Inhaler Testing Solutions by Copley
Inhaler Testing Solutions by Copley
Inhaler Testing
METERED-DOSE INHALERS • DRY POWDER INHALERS
NEBULISERS • AQUEOUS DROPLET INHALERS • NASAL PRODUCTS
2021 EDITION
Inhaler Testing About Us
About Us
Copley: Driving Results for Over 75 Years
Founded in 1946 in Nottingham, UK, Copley remains family owned and managed.
We are recognised as the world’s leading manufacturer of inhaler test equipment, The
in addition to being a trusted provider of test instrumentation for other
pharmaceutical dosage forms. Copley
We continue to work closely with industry groups and These commitments are exemplified by our investment in the Promise
leading experts to bring relevant new products to ISO 9001:2015 Quality Management System for which we
market, with all equipment backed by expert training have certification to the latest standard for all aspects of our
and lifetime support. business, including equipment design. Innovative
Committed to excellence, we aim to deliver exemplary Copley customers benefit from: Innovative product design features ensure ease-of-use
service for an outstanding customer experience. and maximum productivity by streamlining workflows.
• High quality pharmaceutical testing equipment, designed,
We deliver pharmaceutical testing equipment with manufactured and tested in the UK
the necessary accuracy and reproducibility hard-
wired into its design by adopting the same Quality
• Product lifetime support from our friendly and experienced Compliant
technical support team
by Design (QbD) principles that our customers rely Products are certified to quality standards defined by global
on to control product performance. Continuous • First-class training and education pharmacopoeias and regulators, ensuring data integrity.
improvement is a core element of this approach and
we strive to exceed the expectations of the industry,
not only by enhancing equipment performance but Trusted
also through unrivalled service.
Robust design and manufacture from a company with over 75
years’ experience guarantees product reliability and longevity.
Copyright
This edition of the Copley Scientific Limited brochure Copley Scientific Limited does not assume any
is copyright 2021. All rights reserved. liability arising out of the application or use of any
product described herein. Neither does it convey any
No portion of this brochure may be reproduced
licence under its patent rights nor the rights of others.
without the permission of Copley Scientific Limited.
Copley Scientific Limited reserves the right to make Any third party documentation or organisation
changes without notice to any products herein to mentioned herein is referential only and implies no
improve reliability or design. company or product endorsement from, or affiliation
with, Copley Scientific Limited.
2 3
03
Inhaler Testing Contents
Contents
Contents
Introduction 2 Delivered Dose Uniformity 18 Ancillaries 154 Special Applications 252
4 5
Inhaler Testing Orally Inhaled &
Nasal Drug Products
Spacers/VHC: Coordinated v
Nebuliser F Nasal Powder Uncoordinated use
Performance is optimal and directly comparable
with a standard MDI if the patient inhales from the
spacer/VHC as the device is actuated. This is called
‘coordinated use’.
In contrast, the worst case scenario is if actuation
coincides with exhalation, i.e. ‘uncoordinated use’.
6 7
Inhaler Testing Orally Inhaled &
Nasal Drug Products
Pre-Metered Unit Dose Device-Metered Use electricity to vibrate a Use a compressed air supply Use ultrasonics to generate
piezoelectric crystal at high to atomise the liquid drug droplets which are then pushed
frequency. The resultant formulation to produce a fine through a static or vibrating
vibrations are transmitted to a mist using the Bernoulli principle. mesh or plate (either electro-
reservoir containing the liquid formed or laser drilled) to form a
Can be subdivided into three
drug formulation, creating a cloud prior to inhalation.
types depending on their output
series of waves from which
during exhalation. Some mesh nebulisers
liquid droplets separate to form
incorporate sensing devices to
an aerosol.
detect the patient’s inspiration
The dose is pre-measured The pre-measured dose in the The drug is contained in a
in order to provide breath-
during manufacture (for form of a gelatine capsule or reservoir within the device
enhanced, breath-activated or
example, blisters, capsules or blister is loaded by the patient which measures each dose
breath-integrated systems.
similar cavities). prior to use. on actuation.
TOP
TIP Some DPIs actively generate the aerosol, reducing dependence on patient inhalation, whilst simultaneously improving
Standard Breath-Enhanced Breath-Actuated
the accuracy and reproducibility of the delivered dose.
Such devices are normally termed ‘active’ DPIs and are particularly useful where the patient’s own inspiration capability Constant output throughout Continuous aerosolisation Aerosol produced only
is compromised. Assistance normally comes in the form of pressurised/compressed air or through vibrations generated the respiratory cycle. but provides higher output during inhalation.
by a piezoelectric transducer. during inhalation.
8 9
Inhaler Testing Orally Inhaled &
Nasal Drug Products
ADIs (often known as “Inhalation Metered Sprays’’ or “Soft Mist®” Inhalers) actively Directly targets the site of action Rapid onset of drug action Drugs effective in relatively low doses
aerosolise the liquid, forming a ‘soft mist’ to overcome these problems. These inhalers
generally deliver a higher fine particle fraction than MDIs or DPIs. However, as with any
multi-dose liquid system, microbial contamination can be a problem. Fewer side effects Avoids first pass metabolism Non-invasive administration
ADIs do not use a propellant to aerolise the liquid. Methods of aerosol generation include: Such drugs include treatments for diverse applications such as diabetes, erectile dysfunction, migraine,
(a) Forcing liquid through a nozzle (c) Thermal generation osteoporosis and for vaccine delivery.
As far as testing is concerned, most ADIs are treated as MDIs unless their particular
Orally Inhaled Drug Product Applications
design dictates otherwise. Orally inhaled drugs are becoming increasingly popular as a means of delivering local
or systemic therapy via the lungs.
Mechanical metered-dose spray Nasal aerosols are propellant-based Available in both multi- and unit-dose More recently attention has focused on two other areas:
pumps are designed to deliver an and directly analogous to pressurised formats, powder-based devices offer
accurate and consistent dose to MDIs. An angled nosepiece or nozzle preservative-free delivery and can Systemic Circulation Central Nervous System
the user. facilitates insertion into the nostril. produce longer nasal retention times
than liquids. The potential rapid drug absorption The potential of the “Nose
Multi-dose spray pumps have
into the systemic circulation to Brain” entry to the central
dominated the nasal market and Powder-based nasal sprays are ideal
provided by the turbinates and nervous system presented
are widely available through a for peptides, hormones and antigens
(more stable) than liquid formulations
lymphoid tissues located at the by the olfactory region at the
number of device manufacturers.
and where high dose concentrations back of the nasal cavity. This is top of the nasal cavity for the
Unit-dose devices that deliver already in use in a number of treatment of, for example,
are required.
one or two shots (one per nostril),
areas, e.g. migraine and pain relief, diseases of aging such as
are usually based on the syringe
osteoporosis, vaccines. Alzheimer’s Disease.
principle.
10 11
Inhaler Testing Organisations and their Roles
Organisations
and their Roles
The ultimate responsibility for the safety, quality and efficacy of medicines Additionally, the FDA has been focusing on further characterization. The goal of this initiative is to provide
and medical devices lies with the various national regulatory bodies designated strategies to support the development of generics, notably greater understanding of the complex interactions between
to safeguard public health. complex generics like OINDPs. The document “Alternative device, formulation, and patient factors, and eventually be
In Vitro Bioequivalence (BE) Pathways Which Can Reliably able to predict the therapeutic behaviour based on these in
Ensure In Vivo Bioequivalence of Product Performance vitro characteristics”.
Regulatory Bodies in the European Union, China, Japan and USA. with a Generic.” (Generic Drug User Fee Amendments
In April 2018, FDA published a new Draft Guidance for
At present, there are no worldwide standards that are (CDER) in respect of medicines and the Center for (GDUFA)) states, “Additional research is ongoing to explore
Industry for comment (Revision 1) entitled “Metered Dose
specifically applicable to OINDPs. Devices and Radiologic Health (CDRH) in respect of physicochemical API properties and device characteristics
Inhaler (MDI) and Dry Powder Inhaler (DPI) Products -
medical devices. to demonstrate structural similarities (Q3) between test
In Europe, the responsibility for the regulation of Quality Considerations”.
and reference Dry Powder Inhaler (DPI), Metered Dose
medicines and medical devices lies with the European The relevant current thinking from the FDA is reflected Inhaler (MDI), and nasal products. A series of projects are This guidance which covers both quality and performance
Medicines Agency (EMA) in the form of the Committee in the following regulatory Guidelines for Industry: exploring these Q3 characteristics, using Morphologically issues as well as CMC information is a revision of the
for Medicinal Products for Human Use (CHMP). Directed Raman Spectroscopy (MDRS) in conjunction previous 1998 Guidance “updated to reflect current
• CDER (1998), “Metered-Dose Inhaler (MDI) and
The EMA was set up in 1995 to harmonise the work of Dry Powder Inhaler (DPI) Drug Products”, Chemistry, with in vitro dissolution, more realistic Aerodynamic standards and requirements to enhance understanding of
existing national regulatory bodies in Europe. Manufacturing and Controls Documentation – Draft Particle Size Distribution (APSD) measurement under appropriate development approaches for these products
realistic in vitro testing conditions, and particle surface consistent with the quality by design (QbD) paradigm”.
The main guidance from the EMA relating to OINDPs is • CDER (2001), “Sterility Requirements for
contained in two guidelines: Aqueous-Based Drug Products for Oral Inhalation”,
Small Entity Compliance ICH Quality Guidelines
• CPMP (2006), “Guideline on the Pharmaceutical
Quality of Inhalation and Nasal Products” • CDER (2002), “Nasal Spray and Inhalation Solution,
Suspension and Spray Drug Products”, Chemistry, Q1A - Q1F Stability Q7 - Good Manufacturing Practice
• CPMP (2009), “Guideline on the requirements for
Manufacturing and Controls Documentation
clinical documentation for orally inhaled products
(OIP) including the requirements for demonstration • CDER (2003), “Integration of dose-counting Q2 - Analytical Validation Q8 - Pharmaceutical Development
of therapeutic equivalence between two inhaled mechanisms into MDI products”, Clinical Medical
products for use in the treatment of asthma and
• CDER (2003), “Bioavailability and bioequivalence Q3A - Q4B Impurities Q9 - Quality Risk Management
chronic obstructive pulmonary disease (COPD)
studies for nasal sprays for local action”,
in adults and for use in the treatment of asthma in
Biopharmaceutics – Draft
children and adolescents” Q4 - Q4B Pharmacopoeias Q10 - Pharmaceutical Quality System
Since December 2013, the FDA has issued a series
These guidelines give a comprehensive list of the
of product specific guidance relating to various
parameters that are critical to the safety, quality and Q5A - Q
5E Quality of Q11 - D
evelopment and Manufacture
active pharmaceutical ingredients (APIs) including
efficacy of the final product dependent on the specific Biotechnological Products of Drug Substances
Fluticasone Propionate (FP), Salmeterol, Tiotropium,
type of inhaled or nasal preparation concerned.
and Albuterol, amongst others, intended to help
Q6A - Q6B Specifications Q12 - Lifecycle Management
A similar regulatory function is provided by the generic manufacturers navigate the Abbreviated
Chinese FDA (CFDA) in China and the Ministry of New Drug Application (ANDA) process (see Special
Q13 - Continuous Manufacturing of
Health, Labour and Welfare (MHLW) in Japan. Applications, page 252). Drug Substances and Drug Q14 - Analytical Procedure Development
In the USA, the regulatory function is performed by Products
12 13
Inhaler Testing Organisations and their Roles
14 15
Inhaler Testing Organisations and their Roles
c) Chinese Pharmacopoeia (ChP) Expert Groups Organisational Chart: Guidelines and Regulations
The ChP has four chapters contained within its Volume IV In addition to the above, there are a number
applicable to OINDPs, <0111>, <0112>, <0113> and <0951>, plus Metered-Dose Dry Powder Aqueous
of industry and quasi-industry expert groups Nasal Products Nebuliser
five drug specific monographs. Inhaler (MDI)* Inhaler (DPI) Droplet Inhaler
whose role is to assist the regulatory bodies in
Chapter <0111> relates to general requirements applicable establishing best practice in their thinking Regulatory
to MDIs, DPIs and nebulisers (incl. DDU) whilst <0951> and guidance.
describes those methods relating to APSD measurement Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products (2006)
for OINDPs. European Pharmaceutical Aerosol Group (EPAG) EMA
Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP) including the Requirements for
Guidelines
d) Japanese Pharmacopoeia (JP) Demonstration of Therapeutic Equivalence between Two Inhaled Products for use in the Treatment of Asthma and Chronic
A group of 28 member companies active in the OINDP Obstructive Pulmonary Disease (COPD) in Adults and for use in the Treatment of Asthma in Children and Adolescents (2009)
The JP has two chapters related to OIPs, “Chapter <6.14> on market within Europe, formed to establish scientifically
Metered-Dose Inhaler (MDI) & Dry Powder Inhaler (DPI)
Delivered Dose Uniformity” and “Chapter <6.15> on Particle based best practice, provide consensus comment to
Products (2018) - Quality Considerations
industry and government agencies on safety and quality FDA Draft
Size Distribution”. In addition to these, a General Chapter Guidance for
issues, and recommend harmonised standards and Nasal Aerosols and
“G6.4 General Information” is available and applicable Industry Nasal Sprays for Local
to OINDPs. methodology. Copley is an invited member of the cascade Action (2003)
impactor sub-team.
Nasal Spray, Inhalation
FDA Guidance Solution, Suspension
for Industry & Spray Drug Products
Device Safety, Quality and Efficacy – (2002)
Expert Groups
European
EPAG
Pharmaceutical
European based industry expert group involved in orally inhaled and nasal drug products
Aerosol Group (EPAG)
International
Pharmaceutical
IPAC-RS
Consortium on
US based industry expert group involved in orally inhaled and nasal drug products
Regulation
& Science (IPAC-RS)
Product Quality
PQRI
Research Institute
A collaborative research organisation involving FDA’s CDER, industry and academia
(PQRI)
16 17
Inhaler Testing Delivered Dose Uniformity
Delivered Dose
Uniformity (DDU)
One of the four Critical Quality Attributes (CQAs) that determine the DDU Over the Entire Contents
safety, quality and efficacy of orally inhaled and nasal drug products Both the European Pharmacopoeia (Ph. Eur.) and United States
(OINDPs) as discussed in the previous chapter, delivered dose is the total Pharmacopoeia (USP) state that DDU tests should be carried out on
amount of drug emitted from the drug device that is available to the user, all orally inhaled products (OIPs) and that in the case of multiple-dose
when the device is actuated correctly. devices* tests should be carried out throughout the life of the inhaler i.e.
The delivered dose is measured by firing the drug device into a sampling apparatus containing a dose uniformity over the entire contents.
filter. The dose is captured, dissolved in solvent and an aliquot is then analysed, normally using
In the case of [Link]., for example, this involves the collection of 10 doses throughout the
high pressure liquid chromatography (HPLC).
life of each individual inhaler: three doses at the beginning, four in the middle and three
Each OINDP dose typically contains a mixture The uniformity of the delivered dose, or DDU of at the end (see below).
of one or more active pharmaceutical an OINDP must be ensured within and between
* In the case of Ph. Eur., for DPIs this only applies to reservoir type devices.
ingredients (API) together with excipients devices. A number of tests have been defined
designed to help with dose delivery to the by the various regulatory authorities, which are
patient. It is critical to assess that the API designed to demonstrate: Example: Ph. Eur. DDU Over the Entire Contents Requirements
dosage delivered is consistent, or ‘uniform’ with
Inhaler Life Beginning Middle End
each administration to ensure the correct drug
amount is delivered to the patient each time. No. required doses 3 shots 4 shots 3 shots
Inter-batch dose Intra-dose consistency Dose no. 2, 3, 4 99, 100, 101, 102 198, 199, 200
consistency for multi-dose inhalers
throughout device life 200 labelled doses 190 shots to waste
Similar testing requirements exist for other pharmacopoeias and regulatory guidance (see
page 12). To obtain the required doses for analysis, the remaining contents of the inhaled
device must be wasted (and done so appropriately, i.e. reproducibly and safely).
18 19
Inhaler Testing Delivered Dose Uniformity
Collection Devices for DDU Testing DUSA for MDIs, BAIs, ADIs and Nasal Aerosols
Depending on the type of inhaler device under test, different apparatus set-ups are required.
The key collection devices are highlighted below. For further information about device-specific The DUSA for MDIs consists of a sample collection tube, a filter to capture the delivered dose and a connector to
connect the DUSA with the wider test set-up. It has been designed to enhance productivity and ensure ease-of-
testing, please proceed to the relevant sections within this chapter. use. The DUSA for MDIs can also be used to test BAIs, ADIs and nasal aerosols.
B
D Filter H MDI
During testing, air is drawn through the sampling apparatus F
to broadly simulate inhalation. Test conditions are therefore
dependent on device type.
20 21
Inhaler Testing Delivered Dose Uniformity
The DUSA for DPIs is a larger version of the DUSA for MDIs and is designed specifically to sample at During testing, air is drawn through the sampling apparatus to broadly
flow rates up to 100 L/min. It is also used to characterise the flow resistance of DPIs. The pressure simulate inhalation. A critical flow controller is required to control air flow
tap (P1) in its wall is used to connect a critical flow controller to measure the pressure drop across supply to the inhaler and ensure critical (sonic) flow conditions during testing.
the device. The DUSA for DPIs can also be used to assess nasal powders.
Vacuum Sample
A E
Connector Collection Tube Quick-Release
Air Flow Direction
A C Connectors
supplied as
B Rinsing Cap F Pressure Tap (P1) standard
I Rinsing Cap
G
F
H
Vacuum Pump Tubing Critical Flow Controller Filter DUSA Collection Mouthpiece Inhaler
Tube Adapter
22 23
Inhaler Testing Delivered Dose Uniformity
test conditions
Used to angle the device
Waste doses are captured in a disposable cartridge under test to a position
which collects and traps the contents in an integral representative of
HEPA filter, retaining 99.97% of particles over 0.3 in vivo usage
microns in diameter.
24 25
Inhaler Testing Delivered Dose Uniformity
26 27
Inhaler Testing Delivered Dose Uniformity
Pharmaceutical Development:
• DDU Through Container Life
• DDU Over Patient Flow Rate Range
Guideline on the Pharmaceutical Quality of
EMA Product Manufacture:
Inhalation and Nasal Products 2006
• Mean Delivered Dose
• Delivered Dose Uniformity
• Content Uniformity / Uniformity of Dosage Units
Metered Dose
DDU Over the Entire Contents
1st Test Tier 1st Test Tier 2nd Test Tier 2nd Test Tier
Organisation
No. of Inhalers Criteria No. of Inhalers Criteria
the aerosolisation and dispersion mechanisms are dependent on the force generated 10 Inhalers/
1 prime
by the propellant, rather than the patient’s inspiratory effort. Therefore, for MDIs, the USP
1 beginning of life
N/A N/A N/A
test flow rate is fixed at an arbitrary value of 28.3 L/min. 1 end of life
28 29
Inhaler Testing Delivered Dose Uniformity
DDU of MDIs: Manual Test System Set-Up DDU of MDIs: Manual Test System Component Parts
The minimum set-up for DDU testing as litres; this being the volume of air adjudged to be typical
of the average patient.
specified by the Ph. Eur. comprises a sample
collection tube, fitted at one end with a This additional criterion can be met by positioning
an electronically operated timer controlled two-way Dose Uniformity Sampling Apparatus
suitable mouthpiece adapter to accept the (DUSA) for MDIs
solenoid valve, such as that incorporated in the Breath
inhaler under test and connected at the Actuation Controller BAC 100i. See page 21
other end to a vacuum pump capable of
continuously drawing 28.3 L/min through DDU for MDIs: Test Specifications
the inhaler.
Flow Rate (Q) 28.3 L/min
In addition to the specifications laid down by the Ph.
Air Volume (Ph. Eur./EMA) Not defined In addition to the DUSA for MDIs, the following is needed to complete a fully-operational test set-up for the
Eur., the FDA recommends and the USP specifies that
delivered dose testing of MDIs:
the volume of air to be sampled should not exceed 2 Air Volume (USP/FDA) 2 litres
Vacuum Pump
A B C Designed for optimal operation at the low flow rates required for MDI
D testing, the Low Capacity LCP6 Vacuum Pump represents the latest in
high performance, low maintenance, vacuum pump technology. Our
E Vacuum Pump range is specifically designed for use in the testing of
OINDPs in accordance with pharmacopoeial requirements.
F See page 188 for further information about our Vacuum Pump range.
H
Breath Actuation Controller (BAC)
Ensuring that the volume of air sampled does not exceed
pharmacopoeial specifications, the Breath Actuation Controller
BAC 100i contains an electronically operated, timer-controlled
Breath Actuation Inhaler Testing
A Vacuum Pump B
Controller
C
Workstation (ITW)
D Flow Meter E Mouthpiece Adapter two-way solenoid valve and is positioned between the DUSA
and vacuum pump.
Waste Shot
F DUSA for MDIs G H Switching Valve
Collector See page 172 for further information about our Flow Controller range.
Related Accessories
TOP
TIP The BAC 100i can also be used for the testing of Breath-Actuated (or Breath-Operated) MDIs. In this case,
the BAC 100i is used to initiate the flow, simultaneously triggering the breath-actuated inhaler.
+ +
Flow Meter
Used for establishing accurate and consistent inlet flow rate
during testing, our range of Flow Meters measure and control
flow rates to the accuracy specified by the pharmacopoeias.
DUSA Collection Tube Stand Temperature and Relative Humidity Sensor MDI Actuation Sensor/Footswitch
Designed for the convenient transfer of Ideal for measuring environmental Suitable for most commercially available MDI canisters, See page 184 for further information about our range of
multiple DUSA for MDIs around test conditions. See page 179. the MDI Actuation Sensor connects directly to the
the laboratory. See page 21 Breath Actuation Controller BAC 100i to ensure precise Flow Meters.
synchronisation of MDI actuation. Alternatively, a Footswitch
can be attached to trigger actuation. See page 179.
30 31
Inhaler Testing Delivered Dose Uniformity
Mouthpiece Adapter
Moulded from high quality silicone rubber, our Mouthpiece Adapters
DecaVertus
guarantee an airtight seal between the inhaler and the test apparatus.
For a list of available Mouthpiece Adapters see page 203. Accepting up to 10 inhalers per run, the DecaVertus
is a high-throughput shake and fire-to-waste system, ideal
Custom Mouthpiece Adapters are available upon request. for alleviating the burden of tedious through-life testing.
• The test methods used to monitor pharmaceuticals must meet proper standards of
accuracy and reliability
• Companies should establish procedures to ensure the fitness for use of instruments
that generate data supporting product testing
Inhaler Testing Workstation Waste Shot Collector
Copley provides a range of qualification documentation, services and tools to meet with Switching Valve
these requirements.
See page 270 for further information
See page 302 for further information. about the Vertus and Decavertus range.
32 33
Inhaler Testing Delivered Dose Uniformity
Related Applications
We also offer a range of equipment for additional MDI testing application support:
For better in vitro-in vivo For cold Freon® effect testing For USP product-specific
correlation (IVIVC) testing See page 247 monograph testing
See page 214 See page 260
Semi-Automation Tools
Eliminate Increase
Improve efficiency Reduce variability
handling errors testing capacity
DUSA Shaker
Holding up to 21 MDI DUSA collection tubes, the DUSA
shaker automates the internal rinsing of the tubes to ensure
full, fast and repeatable drug dissolution and drug recovery
from internal surfaces.
See page 282 for further information.
34 35
Inhaler Testing Delivered Dose Uniformity
A Mouthpiece
B Spacer/VHC
C Inhaler
a Spacer/VHC FDA
MDI & DPI Products - Quality Considerations
Draft Guidance 2018
Effect of Flow Rate and Inhalation Delay
on MDIs with Spacers
Add-on devices such as spacers, VHCs and reverse VHCs reduce or eliminate the need
for coordination between actuation and inhalation and are widely used together with USP Chapter <1602>
Mass of drug delivered - fully coordinated
and fully uncoordinated
MDIs to overcome coordination issues.
When a patient uses an MDI without an add-on device, As the use of add-on devices has grown, the regulatory
the drug particles contained within the delivered dose authorities have become increasingly aware of the need
are inhaled almost instantaneously as the formulation to test with add-on devices as distinct from MDIs alone.
Table 1: Representative Tidal Breathing Patterns
is aerosolised. In contrast, when an add-on device such
The amount of drug received by the patient using an Paediatric Adult
as a spacer or VHC is used, the patient inhales the drug
add-on device with an MDI will be directly influenced
from a reservoir of aerosolised particles. Parameter Neonate Infant Child Normal 1 Normal 2
by the inhalation profile of the user concerned. For
The additional dead volume provided by this reservoir that reason, tests call for the application of specific Tidal Volume (mL) 25 50 155 770 500
allows aerosol expansion, but also an opportunity breathing profiles to reflect the physiology of the
Frequency (cycles/min) 40 30 25 12 13
for particle impaction, settling and/or electrostatic intended user, see Table 1.
deposition within the chamber itself, all of which can I/E Ratio 1:3 1:3 1:2 1:2 1:2
change the delivered dose. Minute Volume (mL) 1000 1500 3875 9240 6500
For DDU over the entire contents testing of MDIs with a spacer/VHC and a facemask, see page 238.
36 37
Inhaler Testing Delivered Dose Uniformity
DDU of MDIs with a Spacer/VHC: DDU of MDIs with a Spacer/VHC: Test System Component Parts
In the case of VHCs, tests are also carried out to compare the dose received when use is coordinated
or uncoordinated with device actuation, to assess the impact of valve operation.
In addition to the Filter Holder, the following is needed to complete a fully-operational test set-up for the
A B C delivered dose testing of MDIs with a spacer/VHC.
Breathing Simulator
Providing breathing profiles more representative of in vivo
behaviour than conventional systems offering a constant
flow rate, the Breathing Simulator Model BRS 100i is ideal for
assessing the effects of a spacer or VHC on the DDU of MDIs.
Alternatively, the higher capacity Breathing Simulator Model
BRS 100i
200i can be used to access expanded functionality including
the capability to apply user-defined profiles.
Find out more about our range of Breathing Simulators BRS 200i
A Breathing Simulator
on page 156.
B Filter Holder
C Mouthpiece Adapter
Mouthpiece Adapter
Moulded from high quality silicone rubber, our Mouthpiece Adapters
guarantee an airtight seal between the spacer/VHC and the test
apparatus. For a list of available Mouthpiece Adapters see page 203.
Related Accessories
TOP Custom Mouthpiece Adapters are available upon request.
TIP The constant 28.3 L/min air flow rate applied during the
testing of MDIs is replaced by a specific patient relevant
tidal breath profile more representative of the conditions
applied by the patient when using an add-on device.
38 39
Inhaler Testing Delivered Dose Uniformity
Qualification
GMP regulations require that
• The test methods used to monitor pharmaceuticals must meet proper standards of
accuracy and reliability
• Companies should establish procedures to ensure the fitness for use of instruments
that generate data supporting product testing
Related Applications
We also offer a range of equipment for additional MDIs with a spacer/VHC
testing application support:
40 41
Inhaler Testing Delivered Dose Uniformity
Pharmaceutical Development:
• DDU Through Container Life
• DDU Over Patient Flow Rate Range
Guideline on the Pharmaceutical Quality of
EMA Product Manufacture:
Inhalation and Nasal Products 2006
• Mean Delivered Dose
• Delivered Dose Uniformity
• Content Uniformity / Uniformity of Dosage Units
Inhalers (DPIs)
Organisation
No. of Inhalers Criteria No. of Inhalers Criteria
Secondary bronchi
1 Inhaler/10 doses 9/10 doses to be 75-125% 27/30 doses to be 75-125%
and all to be 65-135% of 2 inhalers/20 doses and all to be 65-135% of
DDU for DPIs: Test Specifications Terminal bronchi Ch.P. (MDIs) and Multidose DPIs) Average Delivered Dose Average Delivered Dose
20 inhalers/1 dose of each
10 inhalers/1 dose of each Mean to be 80-120% of LC* Mean to be 80-120% of LC*
Flow Rate (Q) Device dependent (4 kPa)
Alveoli
� 96 kPa (lungs) 9/10 to be 75-125% 27/30 doses to be 75-125%
Air Volume (Ph. Eur./EMA) 4 litres
of Mean Value of Mean Value
JP 1 Inhaler/10 doses All to be 65-135% 2 inhalers/20 doses All to be 65-135%
Air Volume (USP/FDA) 2 litres of Mean Value of Mean Value
Mean to be 85-115% of LC* Mean to be 85-115% of LC*
42 43
Inhaler Testing Delivered Dose Uniformity
DDU of DPIs: Test System Set-Up DDU of DPIs: Test System Component Parts
The basic requirements for DPI DDU testing are the same as for MDI testing, namely DUSA,
mouthpiece adapter, vacuum pump and flow meter. However, a critical flow controller (e.g.
Critical Flow Controller TPK 100i) to measure the pressure drop across the device and control Dose Uniformity Sampling Apparatus
the flow conditions during testing is also required. (DUSA) for DPIs
This is mandatory because most DPIs are passive varying degrees of flow resistance, i.e. some require more See page 22
breath-actuated devices which rely on the patient’s effort to inhale through than others.
inspiration rather than a propellant for dose
Find out more about critical flow control on page 172.
aerosolisation and delivery. The testing of DPIs is further
complicated by the fact that different inhalers provide In addition to the DUSA for DPIs, the following is needed to complete a fully-operational test set-up
for the delivered dose testing of DPIs:
A B C
D
Vacuum Pump
Ideal for the higher, sonic flow rate testing requirements of
E
DPIs, the High Capacity HCP6 and Super Capacity SCP6 Vacuum
Pumps represent the latest in high performance, low maintenance,
F vacuum pump technology. Our Vacuum Pump range is specifically
designed for use in the testing of OINDPs in accordance with
G pharmacopoeial requirements.
See page 188 for further information about our Vacuum Pump range.
H
+ +
Flow Meter
Used for establishing accurate and consistent inlet flow rate
during testing, our range of Flow Meters measure and control
DUSA Collection Tube Stand Temperature and Relative Humidity Sensor Footswitch flow rates to the accuracy specified by the pharmacopoeias.
Designed for the convenient transfer of Ideal for measuring environmental Connecting directly to the Critical Flow Controller
multiple DUSA for DPIs around test conditions. See page 183. TPK 100i, the Footswitch enables precise
See page 184 for further information about our range
the laboratory. See page 23. synchronisation of DPI device actuation with the of Flow Meters.
onset of flow. See page 183.
44 45
Inhaler Testing Delivered Dose Uniformity
See page 24 for further information about the Waste Shot Collector WSC2.
DUSA Shaker
Mouthpiece Adapter Holding up to 12 DPI DUSA collection tubes, the DUSA shaker
automates the internal rinsing of the tubes to ensure full,
Moulded from high quality silicone rubber, our Mouthpiece Adapters
fast and repeatable drug dissolution and drug recovery from
guarantee an airtight seal between the inhaler under test and the test
internal surfaces.
apparatus. For a list of available Mouthpiece Adapters see page 203.
See page 282 for further information.
Custom Mouthpiece Adapters are available upon request.
46 47
Inhaler
Inhaler
Testing
Testing Delivered Dose Uniformity
Chapter 2.9.44. Preparations for Nebulisation: Ph. Eur. : Active Substance Delivery Rate
Ph. Eur.
Characterisation Total Active Substance Delivered
Nebulisers
Chapter <1601> Products for Nebulization - Drug Substance Delivery Rate
USP
Characterization Tests Total Drug Substance Delivered
The delivered dose testing of nebulisers is carried out to determine the total amount JP - -
of drug a patient might be expected to receive during a treatment period, rather than
through one inhalation.
Given the mode of operation of nebulisers, well-defined reliably achieved using breathing simulators
Table 2 : Breathing Simulator Specifications for Nebuliser Characterisation Tests
tidal breathing profiles for specific patient types are (see page 156).
specified for testing (see Table 2). These profiles can be Adult Neonatal Infant Child
48 49
Inhaler Testing Delivered Dose Uniformity
DDU of Nebulisers: Test System Set-Up DDU of Nebulisers: Test System Component Parts
A B C D
In addition to the Filter Holder, the following is needed to complete a fully-operational test set-up for the
delivered dose testing of nebulisers:
Breathing Simulator
Providing breathing profiles more representative of in vivo
behaviour than conventional systems offering a constant
flow rate, the Breathing Simulator Model BRS 100i is ideal
for assessing the DDU of nebulisers. Alternatively, the higher
BRS 100i
capacity Breathing Simulator Model BRS 200i can be used
to access expanded functionality including the capability to
apply user-defined profiles.
BRS 200i
Find out more about our range of Breathing Simulators on
A Breathing Simulator B Angle Adapter C Filter Holder D Mouthpiece Adapter page 156.
Mouthpiece Adapter
Moulded from high quality silicone rubber, our Mouthpiece
Adapters guarantee an airtight seal between the nebuliser and
the test apparatus. For a list of available Mouthpiece Adapters
See page 203.
Custom Mouthpiece Adapters are available upon request.
50 51
Inhaler Testing Delivered Dose Uniformity
Qualification
GMP regulations require that
• The test methods used to monitor pharmaceuticals must meet proper standards of
accuracy and reliability
• Companies should establish procedures to ensure the fitness for use of instruments
that generate data supporting product testing
Related Applications
We also offer a range of equipment for additional nebuliser testing application support:
52 53
Inhaler Testing Delivered Dose Uniformity
A B C
D
Ph. Eur. - -
JP - -
54 55
Inhaler Testing Delivered Dose Uniformity
In addition to the DUSA for MDIs, the following is needed to complete a fully-operational test set-up for the
delivered dose testing of ADIs:
Waste Shot Collector and Switching Valve
A compact vacuum filtration system, the Waste Shot Collector WSC2
Vacuum Pump captures aerosols emitted from repeated actuations of the inhaler, trapping
Designed for optimal operation at the low flow rates required for large quantities of the drug for safe disposal. The Switching Valve is used to
ADI testing, the Low Capacity LCP6 Pump represents the latest in re-direct air flow between the collection device and WSC2 for quick and easy
high performance, low maintenance, vacuum pump technology. Our dose wasting. Please note: only required for multi-dose devices.
Vacuum Pump range is specifically designed for use in the testing of
See page 24 for further information about the Waste Shot Collector WSC2.
OINDPs in accordance with pharmacopoeial requirements.
See page 188 for further information about our Vacuum Pump range.
Mouthpiece Adapter
Moulded from high quality silicone rubber, our Mouthpiece
Adapters guarantee an airtight seal between the inhaler under test
Breath Actuation Controller (BAC)
and the test apparatus. For a list of available Mouthpiece Adapters
Ensuring that the volume of air sampled does not exceed see page 203.
pharmacopoeial specifications, the Breath Actuation Controller BAC 100i
Custom Mouthpiece Adapters are available upon request.
contains an electronically operated, timer-controlled two-way solenoid
valve and is positioned between the DUSA and vacuum pump.
See page 172 for further information about our Flow Controller range.
DDU Over the Entire Contents
In the case of multiple dose devices, tests might need to be carried out throughout the life of the inhaler i.e.
dose uniformity over the entire contents. For further information, see page 24.
Flow Meter
Used for establishing accurate and consistent inlet flow rate Qualification
during testing, our range of Flow Meters measure and control
GMP regulations require that
flow rates to the accuracy specified by the pharmacopoeias.
• The test methods used to monitor pharmaceuticals must meet proper standards of
See page 184 for further information about our range
accuracy and reliability
of Flow Meters.
• Companies should establish procedures to ensure the fitness for use of instruments
that generate data supporting product testing
56 57
Inhaler Testing Delivered Dose Uniformity
Related Applications
We also offer a range of equipment for additional ADI testing application support:
Semi-Automation Tools
Eliminate Increase
Improve efficiency Reduce variability
handling errors testing capacity
DUSA Shaker
Holding up to 21 MDI DUSA collection tubes, the DUSA shaker
automates the internal rinsing of the tubes to ensure full, fast and
repeatable drug dissolution and drug recovery from internal surfaces.
See page 282 for further information.
58 59
Inhaler Testing Delivered Dose Uniformity
B
According to regulatory guidance, for the DDU testing of nasal sprays, the test unit
should be actuated in a vertical or near-vertical, valve-up position with adequate
controls over the critical mechanical actuation parameters, such as actuation force,
speed and rest periods.
Guideline on the Pharmaceutical Quality of Compatible with most nasal sprays, the Vertus Improve nasal spray Increase productivity
EMA Delivered Dose Uniformity Through Container Life testing accuracy and reduce hassle
Inhalation and Nasal Products systems offer analysts complete control over:
and reproducibility
• The speed, angle and duration of shaking,
Ph. Eur. - - ahead of actuation Replicate test Reduce handling errors
methods across and costly out-of-
• Firing force and the speed of application different sites specification results
Guidance for Industry: Nasal Spray and
Inhalation Solution, Suspension and Spray
and release of that force with ease
FDA Content Uniformity
Drug Products - Chemistry, Manufacturing and • The time delay between the end of shaking
Controls Documentation and device actuation
Chapter <601> Inhalation and Nasal Drug
USP Products: Aerosols, Sprays, and Powders - Delivered Dose Uniformity of Product
For more information about the NSDC and NSWC see page 26.
Performance Quality Tests
To find out more about our range of Automated Shake & Fire systems, see page 270.
Ch.P. Chapter 0111 Delivered Dose Uniformity
JP - -
60 61
Inhaler Testing Delivered Dose Uniformity
• The test methods used to monitor pharmaceuticals must meet proper standards of
accuracy and reliability
• Companies should establish procedures to ensure the fitness for use of instruments
Used together with its manual holder, the NSDC that generate data supporting product testing
is a compact dose collection system designed
for manual DDU sampling of nasal sprays. This Copley provides a range of qualification documentation, services and tools to meet
convenient system is ideal for quick, hassle-free these requirements.
DDU testing.
See page 302 for further information.
For ordering information, see page 26.
Related Applications
We also offer a range of equipment for additional MDI testing application support:
62 63
Inhaler Testing Delivered Dose Uniformity
A B C
Nasal Aerosols
G
DDU testing of nasal aerosols follows a similar process to that of MDIs (page 28), since
both use a propellant to deliver a specified volume of active ingredient(s) upon actuation
of a metered valve system. Testing is typically conducted at a fixed flow rate of 28.3 L/
min using a DUSA for MDIs for sample collection. A Vacuum Pump B Breath Actuation C Inhaler Testing D Flow Meter E Nosepiece Adapter
Controller Workstation (ITW)
+ +
Ph. Eur. - -
JP - -
70
64 65
71
Inhaler Testing Delivered Dose Uniformity
Breath Actuation Controller (BAC) See page 203 for further information.
Qualification
Flow Meter GMP regulations require that
Used for establishing accurate and consistent inlet flow rate • The test methods used to monitor pharmaceuticals must meet proper standards of
during testing, our range of Flow Meters measure and control accuracy and reliability
flow rates to the accuracy specified by the pharmacopoeias.
• Companies should establish procedures to ensure the fitness for use of instruments
See page 184 for further information about our range that generate data supporting product testing
of Flow Meters.
Copley provides a range of qualification documentation, services and tools to meet
these requirements.
See page 302 for further information.
66 67
Inhaler Testing Delivered Dose Uniformity
Semi-Automation Tools
Eliminate Increase
Improve efficiency Reduce variability
handling errors testing capacity
DUSA Shaker
Holding up to 21 MDI DUSA collection tubes, the DUSA shaker
automates the internal rinsing of the tubes to ensure full, fast
and repeatable drug dissolution and drug recovery from
internal surfaces.
See page 282 for further information.
68 69
Inhaler Testing Delivered Dose Uniformity
A B C
Nasal Powders F
The minimum requirements for nasal powder delivered dose testing are the same as H
for DPI testing (see page 42), namely DUSA, nosepiece adapter, vacuum pump and
flow meter, plus a critical flow controller to measure the pressure drop across the
device and control flow conditions during testing. A B
Critical Flow
C
Inhaler Testing
D Flow Meter
Vacuum Pump
Controller Workstation (ITW)
The sampling procedure and acceptance criteria for the DDU testing of nasal powders varies according
to the regulatory authority concerned.
Ph. Eur. - - + +
JP - -
70 71
Inhaler Testing Delivered Dose Uniformity
In addition to the DUSA for DPIs, the following is needed to complete a fully-operational test set-up for the Waste Shot Collector and Switching Valve
delivered dose testing nasal powders: A compact vacuum filtration system, the Waste Shot Collector WSC2
captures aerosols emitted from repeated actuations of the inhaler, trapping
large quantities of the drug for safe disposal. The Switching Valve is used to
Vacuum Pump re-direct air flow between the collection device and WSC2 for quick and easy
Ideal for the higher, sonic flow rate testing requirements of nasal dose wasting. Please note: only required for multi-dose devices.
powders, the High Capacity HCP6 Pump represents the latest in high See page 24 for further information about the Waste Shot Collector WSC2.
performance, low maintenance, vacuum pump technology. Our Vacuum
Pump range is specifically designed for use in the testing of OINDPs in
accordance with pharmacopoeial requirements.
See page 188 for further information about our Vacuum Pump range.
Nosepiece Adapter
Special nosepiece adapters are available to accommodate the nasal
powder device and interface it with the test set-up.
Critical Flow Controller (TPK) See page 203 for further information.
Simplify nasal powder test system set-up in accordance with
pharmacopoeial recommendations with the Critical Flow Controller
series. Positioned between the DUSA and vacuum pump, the Critical
Flow Controller TPK 100i ensures critical (sonic) flow conditions during DDU Over the Entire Contents
testing. It measures and records all required parameters required for In the case of multiple dose devices, tests might need to be carried out throughout the life of the inhaler i.e.
testing and for controlling flow conditions. dose uniformity over the entire contents. For further information, see page 24.
See page 172 for further information about our Flow Controller range.
Qualification
GMP regulations require that
• The test methods used to monitor pharmaceuticals must meet proper standards of
Flow Meter accuracy and reliability
Used for establishing accurate and consistent inlet flow rate
• Companies should establish procedures to ensure the fitness for use of instruments
during testing, our range of Flow Meters measure and control
that generate data supporting product testing
flow rates to the accuracy specified by the pharmacopoeias.
See page 184 for further information about our range Copley provides a range of qualification documentation, services and tools to meet
of Flow Meters. these requirements.
See page 302 for further information.
72 73
Inhaler Testing Delivered Dose Uniformity
Semi-Automation Tools
Eliminate Increase
Improve efficiency Reduce variability
handling errors testing capacity
DUSA Shaker
Holding up to 12 DPI DUSA collection tubes, the DUSA shaker
automates the internal rinsing of the tubes to ensure full, fast
and repeatable drug dissolution and drug recovery from
internal surfaces.
See page 282 for further information.
74 75
Inhaler Testing Aerodynamic Particle
Size Distribution
Aerodynamic Particle
Size Distribution An Introduction to
Together with delivered dose, aerodynamic particle size distribution (APSD) Cascade Impaction
is typically identified as a Critical Quality Attribute (CQA) for orally inhaled
and nasal drug products (OINDPs) making it a primary focus for in vitro The cascade impactor is the instrument of choice for both regulators and
characterisation. The APSD of an OINDP defines how particles behave in a pharmacopoeias when measuring the APSD of inhaled drug products due
moving air stream. It is intuitively relevant to the understanding of likely lung to some unique features. Cascade impactors separate a sample on the
deposition and hence potential drug efficacy. basis of particle inertia (which is a function of velocity and aerodynamic
particle size) without the need to know either particle density or shape.
To be therapeutically effective, inhaled drug entrained in the air stream and be exhaled.
particles should ideally be in the range of 1 to The mass of dose delivered at a particle size
5 microns to deposit in the lungs. Particles below 5 microns is normally described as the
more than 5 microns will generally impact in fine particle mass (FPM) or dose (FPD) and is Next Generation Impactor (NGI)
the oropharynx and be swallowed, whereas an important metric for OIPs.
below 1 micron particles will likely remain
Terminal bronchi
TOP TOP
TIP TIP
The term “impactor” is generally used for an instrument where the particles “impact”
Aerodynamic diameter (Dae) D = Dp ½ f(S) on a dry impaction plate or cup. The term “impinger” is used to describe instruments
is the diameter of a sphere of where the particles impinge into a liquid or onto a moist collection surface.
unit density whose behaviour D = Geometric diameter
in an air-stream is the same as p = Particle density
the drug particle. S = Shape factor
D = 3 µm D = 1 µm
D = 3 µm D = 3 µm
76 77
Inhaler Testing Aerodynamic Particle
Size Distribution
Cascade impactors have three unique features which make them the ideal tool for particle size assessment
of inhaled products.
Cascade Impactor NGI Cooler Vacuum Pump
1. Cascade impactors measure 2. Cascade impactors deliver active 3. Cascade impactors capture
aerodynamic particle size data pharmaceutical ingredient (API) the entire dose Example particle sizing
specific measurements system set-up for
Cascade impactors measure Cascade impactors, unlike other
nebulisers
aerodynamic particle size which is Cascade impactors provide a direct sizing techniques, which just
a function of particle density, as means of recovering and quantifying provide a snapshot of part of the
well as the physical dimensions API contained in the aerosol cloud. dose, capture the entire dose
and shape of the particles The aerosol clouds generated by allowing complete characterisation
concerned. This is a more relevant pharmaceutical inhalers typically of the aerosol under test.
parameter when studying how comprise a combination of API(s) and
particles behave in a moving air other excipients or components, but it
stream (as exemplified by the is the size distribution of the API that
respiratory tract) rather than influences efficacy. Cascade impaction
simple “geometric” size. generates an APSD specifically for the
API to meet this informational need.
TOP
Glass Expansion TIP
The pharmacopoeias recommend a number of commercially available impactors for the routine testing of
Chamber A cascade impactor, contrary
OINDPs including the Next Generation Impactor (NGI) and the Andersen Cascade Impactor (ACI), both of which
to common understanding, is
are used globally for the testing of metered-dose inhalers (MDIs), dry powder inhalers (DPIs) and ADIs (Aqueous not a lung simulator. The lung
Droplet Inhalers). Cascade Impactor is a complex organ, with high
humidity, decreasing velocity with
each bifurcation and complex
Induction Port Mouthpiece Adapter Vacuum Pump deposition mechanisms (diffusion and sedimentation,
Vacuum as well as impaction). A cascade impactor is a
For most inhaler-related applications, The inhaler is connected to the Once discharged from the inhaler, the Pump highly discriminatory, reproducible measure of
the inlet to the impactor is fitted induction port by means of a aerosol cloud is drawn through the relative product difference and is therefore ideally
with a right-angled induction port mouthpiece adapter which provides impactor by means of a vacuum pump suited to quality control and in-vitro bioequivalence
designed to act as a simplified throat. an airtight seal between the induction connected to the outlet of the impactor applications. Enhancements to improve the clinical
The dimensions of this induction port port and the device under test. by a suitable length of tubing. realism of testing, in-line with improving in vitro-in
are standardised between the various vivo correlations (IVIVCs), can found on page 214.
pharmacopoeias and serve to ensure
that the aerosol cloud produced by Example particle sizing system set-up for nasal products
the inhaler is sampled in a
Example particle sizing
reproducible manner.
system set-up for MDIs
Example particle sizing system for DPIs
Cascade Impactor
Consists of one or more stages
Cascade Impactor Critical Flow Controller Vacuum Pump
normally arranged in the form of
a ‘stack’, which can be vertical or
horizontal. These separate the particles
entrained in the aerosol stream, into a
series of size bands or fractions in the
respirable range, broadly corresponding
to their likely deposition sites in the
respiratory tract.
78 79
Inhaler Testing Aerodynamic Particle
Size Distribution
80 81
Inhaler Testing Aerodynamic Particle
Size Distribution
Types of TOP
TIP
in the relevant pharmacopoeias, the highly flexible NGI is the cascade impactor
of choice for many laboratories throughout the world.
82 83
Inhaler Testing Aerodynamic Particle
Size Distribution
The sample-laden air flow passes through the NGI in a saw-tooth pattern across stages arranged in a NGI: Component Parts
horizontal plane.
A number of supporting component parts are required in addition to the NGI itself:
Stage 2 Stage 4 Stage 6 MOC Stage 1 nozzle Inter-stage passageway
6 holes 52 holes 396 holes 4032 holes
Removable
impaction cups
NGI Principle of Operation Schematic of Seal Body Showing Orientation of the Various Stages
NGI Preseparator
The NGI requires the use of a preseparator when used with DPIs in order
Interstage passageway Interstage passageway
The cut-off diameters
to next stage from previous stage to catch any powder boluses and large non-inhalable particles. Offering
for the relevant stages
high capacity, high efficiency, two-stage separation, the NGI Preseparator
at volumetric flow rates
Lid provides a sharp and reproducible cut-point of between 10 and 15
of 15, 30, 60 and 100 L/
microns depending on flow rate.
min are shown in the
Seal body
Air Flow table below.
Cup tray
Bottom frame
Filter Holder
Collection cup Multi-nozzle stage
In most cases, the MOC eliminates the need for a final paper
filter, having an 80% collection efficiency of 0.3 micron
NGI Inter-Stage Airflow
particles at 30 L/min. If ultra-fine particles are present and at
flow rates below 30 L/min, then an internal or external filter
holder can be used.
NGI Cut-Off Diameters
15 30 60 100 L/min TOP
TIP
Stage 1 14.10 11.72 8.06 6.12 microns Automation: The 3-part
construction of the NGI Sample Collection Cups
Stage 2 8.61 6.40 4.46 3.42 microns makes it ideal for semi-
Four special types of sample collection cups are available in
automation.
Stage 3 5.39 3.99 2.82 2.18 microns addition to those supplied as standard with the NGI:
See page 266 for further
Stage 4 3.30 2.30 1.66 1.31 microns information on our semi- Gravimetric Cup - for APSD determinations based on sample weight
automation solutions.
Stage 5 2.08 1.36 0.94 0.72 microns Deep Cup - to bypass a stage, obviating impaction
84 85
Inhaler Testing Aerodynamic Particle
Size Distribution
Number of Stages 7
NGI Cup Rack
Operation Method Impaction
For the convenient storage of a full set of NGI Cups, protecting the
critical surfaces from inadvertent damage and dust collection when Inter-Stage Losses Low (<5%)
not in use.
Chemical analysis
- HPLC
Method of Drug Assay
- Ultra Performance Liquid Chromatography (UPLC)
- Infrared Spectroscopy (IR)
86 87
Inhaler Testing Aerodynamic Particle
Size Distribution
Andersen
Cascade Impactor (ACI) ACI with Induction Port A Quick-Release
Connector is supplied
as standard
Well-established and readily accepted by the regulatory authorities, the ACI
has been used for the APSD characterisation of OINDPs for over 30 years. A vertical planar layout
with a small unit footprint
88 89
Inhaler Testing Aerodynamic Particle
Size Distribution
Aerosol Particles
Stage 3
Stage 4
Last Stage Nozzle(s) Stage 5
Stage 6
Collection Plate
Collection Plate
Filter Stage with Filter Designed to collect the large mass of non-inhalable powder boluses emitted
from powder-based inhalers prior to their entry into the impactor, the ACI
Base Preseparator is ideal for DPI testing applications. Preseparators are available for
Vacuum
testing at 28.3, 60 and 90 L/min.
Principle of Operation ACI: Exploded View
Unlike the NGI, the stages of the ACI are arranged vertically. The aerosol flow passes first through the stage at the
top of the impactor, through to the last stage and a final filter at the bottom of the impactor arrangement.
ACI: Accessories
ACI: Modified Configurations
The standard ACI is designed for use at 28.3 L/min. In change in cut-points that would occur for each stage
some cases (particularly with low resistance DPIs), it is with any change to the flow rate. We offer two modified
necessary to operate at flow rates greater than 28.3 L/ configurations of the ACI for operation at calibrated
min, if a pressure drop over the inhaler of 4 kPa is to flow rates of 60 and 90 L/min to help address this. ACI Quick Clamp
be achieved. However, it is important to consider the Constructed from stainless steel, the ACI Quick Clamp enables
quick and efficient adjustment of the ACI plate stack.
90 91
Inhaler Testing Aerodynamic Particle
Size Distribution
Chemical analysis
See page 298.
- HPLC
Method of Drug Assay
- UPLC
- IR
TOP Conversion Kits for the standard 28.3 L/min ACI Spare Parts
TIP 8318 Conversion Kit for 60 L/min operation* 8307 Complete Set of 13 ACI Silicone Rubber O-Rings
All ACIs supplied by Copley are machined to the same precision tolerances in order to guarantee reproducibility 8314 Set of 8 Stainless Steel Collection Plates (28.3 L/min)
8319 Conversion Kit for 90 L/min operation*
between impactors. Each ACI is supplied with a full stage mensuration report (system suitability). 8314-60 Set of 8 Stainless Steel Collection Plates (60 L/min)
8314-90 Set of 8 Stainless Steel Collection Plates (90 L/min)
Component Parts 8316 Box of 100 Glass Fibre Filters
8306 Set of 6 O-Rings for Spring Clamp
Induction Ports 8308 Set of 3 Spring Clamps
8501 USP Induction Port* 8309 Set of 3 PVC End Caps for Spring Clamps
8510 USP Induction Port (One-piece 316 Stainless Steel) 8403 Set of 4 O-Rings for Preseparator
8060 Flow Meter to Induction Port/WSC2 Adapter 8395 ACI Carrying Case
5238 Universal Flow Meter Adapter 8351 Inlet Cone*
8352 Stage -2A*
Preseparators for testing DPIs 8353 Stage -1A (for 90 L/min operation)*
8401 28.3 L/min Preseparator* 8354 Stage -1 (for 60 L/min operation)*
8420 60 L/min Preseparator* 8355 Stage -0*
8420-90 90 L/min Preseparator* 8356 Stage 0*
8357 Stage 1*
8358 Stage 2*
Accessories 8359 Stage 3*
8360 Stage 4*
Cat. No. Description 8361 Stage 5*
8362 Stage 6*
5212 ‘Quick Clamp’ for Andersen Cascade Impactor
8363 Stage 7*
8111 Stand (incl. Base Plate, Boss Head and Clamp)
8364 Stage F (Filter)*
5441 ACI Collection Plate Rack
8365 Base (including Hose Fitting)*
5401 ACI Carrying/Wash Rack
*Please specify Aluminium (A), 316 Stainless Steel (S) or Titanium (T)
when placing your order.
92 93
Inhaler Testing Aerodynamic Particle
Size Distribution
94 95
Inhaler Testing Aerodynamic Particle
Size Distribution
Aerosol Inlet The aerosol stream is drawn into the top of the
MSLI, passing first through Stage 1 which acts as a
preseparator. Particles with sufficient inertia will impact
on the moist surface of the sintered glass disc. Those
Stage 1
with insufficient inertia will pass through to Stage 2. The
same process of impaction and particle selection takes
place until the final filter stage (Stage 5), which captures
Stage 2 any remaining fine particles.
No. of Stages 4
Chemical Analysis
- HPLC
Method of Drug Assay
- UPLC
- IR
96 97
Inhaler Testing Aerodynamic Particle
Size Distribution
Corrosion resistant
Glass Twin Impinger (GTI) inhaler into respirable and non-respirable portions.
Prior to testing, 7 mL of solvent is typically
Retained as Apparatus A in [Link]. 2.9.18 due to its value as a simple and inexpensive Upper Chamber dispensed into the upper impingement chamber
and 30 mL to the lower impingement chamber.
routine quality control tool, the two-stage GTI is ideal for use where batch-to-batch Upper
variability in FPD is required and a coarser test may be acceptable. Impingement The upper impingement chamber (stage 1) is
Chamber
designed such that at a flow rate of 60 L/ min
Its usage is typically restricted to the assessment of nebulisers, MDIs, nasal sprays and DPIs where it can through the impinger, the particle cut-off is 6.4
Liquid
be demonstrated that a flow rate of 60 (+/- 5) L/min is suitable. microns. Particles smaller than 6.4 microns pass into
Vacuum
Source the lower impingement chamber (stage 2).
After the test is complete, the active drug collected
[Link]. 2.9.18 compliant Regular mensuration Lower in the lower impingement chamber is assayed and
Impingement
(Apparatus A) is not required Chamber expressed as a respirable fraction (or percentage) of
the delivered dose.
98 99
Inhaler Testing Aerodynamic Particle
Size Distribution
Number of Stages 1
Y Y Y Y Ph. Eur./EMA
Y N N N USP/FDA
Y N N N JP
Y Y N N Ph. Eur./EMA
Y Y N N USP/FDA
ADI
NGI ACI MSLI GTI Y Y N N ChP
28.3 L/min Y Y N N JP
Flow Rate Range 15 – 100 L/min 60 L/min 30 – 100 L/min 60 L/min
90 L/min Y Y N N Ph. Eur./EMA
Particle Size Range 0.24 – 11.7 microns 0.4 – 9.0 microns 1.7 – 13.0 microns 6.4 microns Nasal Y Y N N USP/FDA
Products
Number of Stages 7 8 4 1 Y Y N N ChP
100 101
Inhaler Testing Aerodynamic Particle
Size Distribution
JP 6.15.5 App 3
Organisation Chapter/Guidance
Ph. Eur. / EMA 2.9.18 App D
Organisation Chapter/Guidance
Ph. Eur. / EMA 2.9.18 App C
+
USP / FDA <601> App 1
ChP -
Organisation Chapter/Guidance
Temperature and Relative Humidity Sensor MDI Actuation Sensor/Footswitch
Ph. Eur. / EMA 2.9.18 App A
Ideal for measuring environmental Suitable for most commercially available MDI canisters,
USP / FDA - test conditions. See page 179. the MDI Actuation Sensor connects directly to the
Breath Actuation Controller BAC 200i to ensure precise
ChP <0951>/App 1 synchronisation of MDI actuation. Alternatively, a
Footswitch can be attached to trigger actuation.
GTI JP - See page 179.
102 103
Inhaler Testing Aerodynamic Particle
Size Distribution
TOP Copley provides a range of qualification documentation, services and tools to meet
TIP The BAC 100i can also be used for the testing of Breath-Actuated (or Breath-Operated) MDIs. In this case, the BAC 100i these requirements.
is used to initiate the flow, simultaneously triggering the breath-actuated inhaler.
See page 302 for further information.
104 105
Inhaler Testing Aerodynamic Particle
Size Distribution
Gentle Rocker
Agitates the NGI Collection Cup Tray in a controlled, repeatable manner to
Vertus II & Vertus Plus ensure complete dissolution of the active drug prior to analysis. See page 287.
Offering high productivity, walkaway
Recommended for:
MDI testing, the Vertus II and Vertus
Plus can be used for APSD sampling
directly with an NGI, ACI or GTI and
Sample Preparation Unit SPU 200i
all without manual intervention. The
Vertus Plus also offers optional shot Simplifies and automates the drug recovery process from induction ports
weight collection. and preseparators. See page 290.
Recommended for:
NGI Assistant
Replaces the need for:
A complete system for drug recovery from the NGI Collection Cup Tray,
Vacuum Pump Breath Actuation Controller Flow Meter Induction Port and Preseparator, boosting analytical throughput. See page 294.
Recommended for:
See page 270 for further information about the Vertus range. Recommended for:
106 107
Inhaler Testing Aerodynamic Particle
Size Distribution
Related Applications
We also offer a range of equipment for additional MDI testing application support:
For better in vitro-in vivo For cold Freon® effect testing For USP product-specific monographs
correlation (IVIVC) testing See page 247 See page 260
Aerodynamic Particle Size Distribution
See page 214
MDIs with a Spacers/VHC
Training, Servicing & Support Due to the potential opportunity for particle expansion, impaction and deposition within
the chamber of add-on devices such as spacers or VHCs, the APSD characteristics may be
We offer a comprehensive range of services from bespoke product design to substantially altered from what is emitted when the MDI is used alone. This potential for change
installation, expert training and technical support, optimising all aspects of must be appropriately assessed.
pharmaceutical testing from start to finish.
Regulations and Guidelines
Organisation Chapter/Guidance
Ph. Eur. / EMA -
NGI ChP -
Training Servicing Support Design
See page 313 See page 304 See page 312 See page 312 JP -
Organisation Chapter/Guidance
Ph. Eur. / EMA -
ChP -
ACI JP -
In Section 3 of USP Chapter <1602> Spacers and Valved Holding Chambers used with Inhalation Aerosols, two tests
are specified relating to the APSD characterisation of add-on devices used with the MDIs:
108 109
Inhaler Testing Aerodynamic Particle
Size Distribution
APSD of MDIs with a Spacer/VHC: APSD of MDIs with a Spacer/VHC: Test System Component Parts
Required for:
Recommended for:
Temperature and Relative Humidity Sensor MDI Actuation Sensor/Footswitch
Ideal for measuring environmental Suitable for most commercially available MDI canisters, the MDI
test conditions. See page 179. Actuation Sensor connects directly to the Breath Actuation Controller
BAC 100i to ensure precise synchronisation of MDI actuation.
Alternatively, a Footswitch can be attached to trigger actuation.
See page 179.
110 111
Inhaler Testing Aerodynamic Particle
Size Distribution
Flow Meter
Data Analysis Software: Inhalytix™
Used for establishing accurate and consistent inlet flow rate during A flexible and fully validated solution for the entry, analysis and reporting of APSD
testing, our range of Flow Meters measure and control flow rates to the
data for all inhaled products.
accuracy specified by the pharmacopoeias.
User-configurable, the software will accept See page 206 for further information about
See page 184 for further information about our range of Flow Meters.
data from standard and customised cascade Inhalytix™.
impactors and impingers, including the NGI,
Required for: ACI, MSLI and GTI.
Recommended for:
Mouthpiece Adapter
Moulded from high quality silicone rubber, our Mouthpiece Adapters Sample Preparation Unit SPU 200i
guarantee an airtight seal between the inhaler/add-on device Simplifies and automates the drug recovery process from induction ports
combination under test and the test apparatus. For a list of available and preseparators. See page 290.
Mouthpiece Adapters see page 203.
Recommended for:
Custom Mouthpiece Adapters are available upon request.
Required for:
NGI Assistant
A complete system for drug recovery from the NGI Collection Cup Tray,
Induction Port and Preseparator, boosting analytical throughput. See page 294.
Recommended for:
Qualification
GMP regulations require that
• The test methods used to monitor pharmaceuticals must meet proper standards of Impactor Cleaning System
accuracy and reliability
Standardises cleaning and drying procedures to help ensure the NGI and ACI
• Companies should establish procedures to ensure the fitness for use of instruments remain in optimum condition throughout their life. See page 298.
that generate data supporting product testing
Recommended for:
Copley provides a range of qualification documentation, services and tools to meet
these requirements.
See page 302 for further information.
112 113
Inhaler Testing Aerodynamic Particle
Size Distribution
Related Applications
We also offer a range of equipment for additional application testing support:
114 115
Inhaler Testing Aerodynamic Particle
Size Distribution
Organisation Chapter/Guidance
Ph. Eur. / EMA 2.9.18 App. E
JP 6.15.5 App 3
Organisation Chapter/Guidance
Ph. Eur. / EMA 2.9.18 App. D
Organisation Chapter/Guidance
Ph. Eur. / EMA 2.9.18 App. A
Temperature and Relative Humidity Sensor Footswitch
USP / FDA -
Ideal for measuring environmental Connecting directly to the Critical Flow Controller TPK
ChP <0951> App. 1 test conditions. See page 183. 100i, the Footswitch enables precise synchronisation of
DPI actuation with the onset of flow. See page 183.
GTI JP -
116 117
Inhaler Testing Aerodynamic Particle
Size Distribution
DON’T
FORGET Required for:
Preseparator
For the collection of large mass, non-inhalable powder boluses
typically emitted from a DPI, prior to entry into the impactor. Flow Meter
Different preseparators are available for the NGI and ACI.
Used for establishing accurate and consistent inlet flow rate during
See pages 85 and 91 respectively. testing, our range of Flow Meters measure and control flow rates to the
Note: Preseparators are not required for APSD testing of DPIs accuracy specified by the pharmacopoeias.
using an MSLI or GTI. See page 184 for further information about our range of Flow Meters.
Required for:
Required for:
118 119
Inhaler Testing Aerodynamic Particle
Size Distribution
Copley provides a range of qualification documentation, services and tools to meet Impactor Cleaning System
these requirements. Standardises cleaning and drying procedures to help ensure the NGI and ACI
See page 302 for further information. remain in optimum condition throughout their life. See page 298.
Recommended for:
Semi-Automation Tools
Eliminate Increase For better in vitro-in vivo For USP product-specific
Improve efficiency Reduce variability
handling errors testing capacity correlation (IVIVC) testing monographs
See page 214 See page 260
Recommended for:
Recommended for:
120 121
Inhaler Testing Aerodynamic Particle
Size Distribution
integrity of the resulting data. Cooling the impactor to of other OINDPs in order to better represent the tidal
approximately 5°C is the recommended method for breathing conditions employed in their use.
overcoming this problem.
Related Accessories
Regulations and Guidelines
Organisation Chapter/Guidance
+
Ph. Eur. / EMA 0671 App. E
JP -
Temperature and Relative Humidity Sensor Footswitch
Ideal for measuring environmental Connecting directly to the Breath Actuation
test conditions. See page 179. Controller BAC 100i, the Footswitch enables precise
synchronisation of nebuliser device actuation with the
onset of flow. See page 179.
122 123
Inhaler Testing Aerodynamic Particle
Size Distribution
NGI Cooler
Next Generation Impactor (NGI) Accommodating the NGI both open and closed, the NGI Cooler
The APSD characterisation of a nebuliser should be conducted using an allows the NGI to be operated in a temperature controlled
NGI. This is because the NGI is calibrated for use at 15 L/min and has environment. Additional space allows for cooling of extra sets
collection cups well suited to retaining liquid droplets. of Collection Cups, so multiple tests can be undertaken in
quick succession.
See page 194 for further information about the NGI Cooler.
Qualification
GMP regulations require that
• The test methods used to monitor pharmaceuticals must meet proper standards of
accuracy and reliability
Breath Actuation Controller (BAC)
• Companies should establish procedures to ensure the fitness for use of instruments
Ensuring that the volume of air sampled does not exceed the
that generate data supporting product testing
pharmacopoeial specifications, the Breath Actuation Controller model
BAC 100i contains an electronically operated, timer-controlled two-
Copley provides a range of qualification documentation, services and tools to meet
way solenoid valve and is positioned between the impactor and
these requirements.
Vacuum Pump to control air flow supply to the nebuliser.
See page 302 for further information.
See page 172 for further information about our Flow Controller range.
Flow Meter
Used for establishing accurate and consistent inlet flow rate during
testing, our range of Flow Meters measure and control flow rates to the
accuracy specified by the pharmacopoeias. See page 184 for further
information about our range of Flow Meters.
124 125
Inhaler Testing Aerodynamic Particle
Size Distribution
Gentle Rocker
Training, Servicing & Support
Agitates the NGI Collection Cup Tray in a controlled, repeatable manner to We offer a comprehensive range of services from bespoke product design to
ensure complete dissolution of the active drug prior to analysis. See page 287. installation, expert training and technical support, optimising all aspects of
Recommended for: pharmaceutical testing from start to finish.
NGI Assistant
A complete system for drug recovery from the NGI Collection Cup Tray,
Induction Port and Preseparator, boosting analytical throughput. See page 294.
Recommended for:
Recommended for:
126 127
Inhaler Testing Aerodynamic Particle
Size Distribution
Organisation Chapter/Guidance +
128 129
Inhaler Testing Aerodynamic Particle
Size Distribution
Flow Meter
Next Generation Impactor (NGI)
Used for establishing accurate and consistent inlet flow rate during
The recommended test set-up is with an NGI. An ACI can also be used
testing, our range of Flow Meters measure and control flow rates to the
for the assessment of ADIs.
accuracy specified by the pharmacopoeias. See page 184 for further
information about our range of Flow Meters.
Required for:
Mouthpiece Adapter
Required for:
Moulded from high quality silicone rubber, our Mouthpiece Adapters
guarantee an airtight seal between the inhaler under test and the test
apparatus. For a list of available Mouthpiece Adapters see page 203.
Custom Mouthpiece Adapters are available upon request.
Breath Actuation Controller (BAC)
Ensuring that the volume of air sampled does not exceed the Required for:
pharmacopoeial specifications, the Breath Actuation Controller BAC
100i contains an electronically operated, timer-controlled two-way
solenoid valve and is positioned between the impactor and Vacuum
Pump to control air flow supply to the inhaler.
Qualification
See page 172 for further information about our Flow Controller range.
GMP regulations require that
• The test methods used to monitor pharmaceuticals must meet proper standards of
Recommended for:
accuracy and reliability
• Companies should establish procedures to ensure the fitness for use of instruments
that generate data supporting product testing
130 131
Inhaler Testing Aerodynamic Particle
Size Distribution
For better in vitro-in vivo For cold Freon® effect testing For USP product-specific
correlation (IVIVC) testing See page 247 monographs
Semi-Automation Tools See page 214 See page 260
Eliminate Increase
Improve efficiency Reduce variability
Gentle Rocker We offer a comprehensive range of services from bespoke product design to
Agitates the NGI Collection Cup Tray in a controlled, repeatable manner to
installation, expert training and technical support, optimising all aspects of
ensure complete dissolution of the active drug prior to analysis. See page 287. pharmaceutical testing from start to finish.
Recommended for:
NGI Assistant
A complete system for drug recovery from the NGI Collection Cup Tray,
Induction Port and Preseparator, boosting analytical throughput. See page 294.
Recommended for:
Recommended for:
132 133
Inhaler Testing Aerodynamic Particle
Size Distribution
C D
Nasal Sprays
Nasal sprays typically produce droplets in the range 20-200 microns, which is outside G
the effective range of cascade impactors. However, most sprays deliver a proportion
(typically <5%) of fine droplets in the <10 micron range.
It is important to quantify the amount of droplets Regulators recommend the use of a cascade impactor A Vacuum Pump B
Glass Expansion
Chamber
Alternative Impactors/Impingers
in this range since it is the amount of dose that can in conjunction with a high volume expansion chamber
Adapter and
penetrate beyond the nasal tract and into the lower to quantify the amount of drug in the <10 micron C
Clamp for ACI
D Flow Meter Fast Screening Glass Twin
respiratory tract or lungs, which may range, to assess the potential risk of deposition Andersen Impinger
be undesirable. in the lungs. E
Nosepiece
F
Andersen Cascade (FSA) (GTI)
Adapter Impactor (ACI)
Inhaler Testing
G
Workstation (ITW)
NGI ChP -
JP -
Organisation. Chapter/Guidance
Ph. Eur / EMA -
Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products —
USP / FDA Chemistry, Manufacturing, and Controls Documentation
ChP -
ACI
JP -
Organisation Chapter/Guidance
Ph. Eur. / EMA -
USP / FDA -
ChP -
GTI JP -
134 135
Inhaler Testing Aerodynamic Particle
Size Distribution
set-up for the APSD measurement of nasal sprays: See page 200 for further information.
Required for:
Vacuum Pump
Designed for optimal operation at the low flow rates required for nasal
spray testing, the Low Capacity LCP6 Vacuum Pump represents the latest
in high performance, low maintenance, vacuum pump technology. Our Adapter and Clamp
Vacuum Pump range is specifically designed for use in the testing of Adapters are available to connect the outlet port of the Glass Expansion
OINDPs in accordance with pharmacopoeial requirements. Chamber to the inlet of the NGI, Inlet Cone of the ACI and the inlet of
the MSLI. Each adapter is supplied with a clamp which allows the Glass
See page 188 for further information about our Vacuum Pump range.
Expansion Chamber to be removed easily from the impactor for assay.
Required for:
Flow Meter
Used for establishing accurate and consistent inlet flow rate during Nosepiece Adapter
testing, our range of Flow Meters measure and control flow rates to the
Special Nosepiece Adapters are available to accommodate the nasal
accuracy specified by the pharmacopoeias.
spray device and interface it with the test set-up.
See page 184 for further information about our range of Flow Meters.
See page 203 for further information.
Required for:
Required for:
136 137
Inhaler
Index Testing Aerodynamic Particle
Size Distribution
The Vertus automated shake, fire and shot waste range is made up of integrated
turn-key solutions for precise, controlled and reproducible nasal spray testing.
Gentle Rocker
Compatible with most nasal sprays, the Vertus II or Improve nasal spray Increase productivity
Agitates the NGI Collection Cup Tray in a controlled, repeatable manner to
Vertus Plus offers analysts complete control over: testing accuracy and reduce hassle
and reproducibility ensure complete dissolution of the active drug prior to analysis. See page 287.
• The speed, angle and duration of shaking, ahead
of actuation Replicate test Reduce handling errors Recommended for:
methods across and costly out-of-
• Firing force and the speed of application and
different sites specification results
release of that force with ease
• The time delay between the end of shaking
and device actuation NGI Assistant
A complete system for drug recovery from the NGI Collection Cup Tray,
Induction Port and Preseparator, boosting analytical throughput. See page 294.
Recommended for:
Replaces the need for:
Flow Meter Vacuum Pump Inhaler Testing Workstation
See page 270 for further information about the Vertus range.
138 139
Inhaler
Index Testing Aerodynamic Particle
Size Distribution
Related Applications
We also offer a range of equipment for additional nasal spray testing application support:
NGI ChP -
JP -
Organisation Chapter/Guidance
Ph. Eur. / EMA -
Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products —
USP / FDA Chemistry, Manufacturing, and Controls Documentation
ChP -
ACI JP -
140 141
Inhaler
Index Testing Aerodynamic Particle
Size Distribution
APSD of Nasal Aerosols: Test System Set-Up APSD of Nasal Aerosols: Test System Component Parts
D
Impactors with 7 or 8 stages are preferred by regulators, as they provide
good APSD resolution. The FSA, a reduced stack plus filter version of the
C
ACI, is also suitable, for analogous reasons; little deposition is expected
E in the lower stages of the impactor.
See page 255 for further information about the FSA.
F
A Vacuum Pump B
Glass Expansion
Chamber
Alternative Impactors/Impingers
C
Adapter and
D Flow Meter
Vacuum Pump
Clamp for ACI Next Generation Fast Screening
Designed for optimal operation at low flow rates required for nasal
Impactor Andersen
E
Nosepiece
F
Andersen Cascade
(NGI) (FSA)
aerosol testing, the Low Capacity LCP6 Vacuum Pump represents the
Adapter Impactor (ACI)
latest in high performance, low maintenance, vacuum pump technology.
G
Inhaler Testing Our Vacuum Pump range is specifically designed for use in the testing
Workstation (ITW)
of OINDPs in accordance with pharmacopoeial requirements.
See page 188 for further information about our Vacuum Pump range.
Required for:
Flow Meter
Used for establishing accurate and consistent inlet flow rate during
testing, our range of Flow Meters measure and control flow rates to the
accuracy specified by the pharmacopoeias.
See page 184 for further information about our range of Flow Meters.
Required for:
142 143
Inhaler Testing Aerodynamic Particle
Size Distribution
Semi-Automation Tools
Eliminate Increase
Improve efficiency Reduce variability
handling errors testing capacity
Recommended for:
Nosepiece Adapter
Special Nosepiece Adapters are available to accommodate Impactor Cleaning System
the nasal aerosol device and interface it with the test set-up.
Standardises cleaning and drying procedures to help ensure the NGI and ACI
See page 203 for further information. remain in optimum condition throughout their life. See page 298.
144 145
Inhaler Testing Aerodynamic Particle
Size Distribution
Related Applications
We also offer a range of equipment for additional nasal aerosol testing application support:
NGI ChP -
JP -
Organisation Chapter/Guidance
Ph. Eur. / EMA -
Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products —
USP / FDA Chemistry, Manufacturing, and Controls Documentation
ChP -
ACI JP -
146 147
Inhaler Testing Aerodynamic Particle
Size Distribution
APSD of Nasal Powders: Test System Set-Up APSD of Nasal Powders: Test System Component Parts
Vacuum Pump
A
Nosepiece
Adapter
B
Induction
Port
Alternative Impactors/Impingers Ideal for the higher, sonic flow rate testing requirements of nasal powders,
the High Capacity HCP6 and Super Capacity SCP6 Vacuum Pumps
Next Generation Critical Flow
C
Impactor (NGI)
D
Controller Fast Screening Andersen represent the latest in high performance, low maintenance, vacuum pump
Andersen Cascade technology. Our Vacuum Pump range is specifically designed for use in the
E Flow Meter F Vacuum Pump (FSA) Impactor (ACI) testing of OINDPs in accordance with pharmacopoeial requirements.
See page 188 for further information about our Vacuum Pump range.
Required for:
148 149
Inhaler Testing Aerodynamic Particle
Size Distribution
Recommended for:
Nosepiece Adapter
Special Nosepiece Adapters are available to accommodate the nasal
Gentle Rocker
powder device and interface it with the test set-up.
Agitates the collection cup tray in a controlled, repeatable manner to ensure
See page 203 for further information.
complete dissolution of the active drug prior to analysis. See page 287.
• The test methods used to monitor pharmaceuticals must meet proper standards of
accuracy and reliability
• Companies should establish procedures to ensure the fitness for use of instruments NGI Assistant
that generate data supporting product testing A complete system for the drug recovery process from the NGI Collection
Cup Tray, Induction Ports and Preseparators, boosting analytical throughput.
Copley provides a range of qualification documentation, services and tools to meet See page 294.
these requirements.
Recommended for:
See page 302 for further information.
Data Analysis Software: Inhalytix™ Standardises cleaning and drying procedures to help ensure the NGI and ACI
remain in optimum condition throughout their life. See page 298.
A flexible and fully validated solution for the entry, analysis and reporting
of APSD data for all inhaled products. Recommended for:
User-configurable, the software will accept See page 206 for further information about
data from standard and customised cascade Inhalytix™.
impactors and impingers, including the NGI,
ACI, MSLI and GTI.
150 151
Inhaler Testing Aerodynamic Particle
Size Distribution
Related Applications
We also offer a range of equipment for additional nasal powder testing application support:
152 153
Inhaler Testing Ancillaries
Ancillaries
This chapter describes the ancillaries required in addition to the Vacuum Pumps
Dosage Unit Sampling Apparatus (DUSA) and cascade impactor to Driving most inhaler testing systems is the vacuum pump.
make up a fully-operational test set-up for determining the Delivered We offer a choice of three Vacuum Pumps dependent on
Dose Uniformity (DDU) and Aerodynamic Particle Size Distribution the system set-up and the capacity required.
(APSD) of orally inhaled and nasal drug products (OINDPs). See page 188
Breathing Simulators
NGI Cooler
Used to apply a more clinically representative breathing profile
(relative to a constant flow rate) during testing, our range of Breathing Designed to maintain the integrity of the APSD data of aerolised
Simulators cover the variety of breathing patterns found in neonatal, droplets by eliminating evaporation induced by the thermal mass
infant, child and adult physiologies. of the impactor, the NGI Cooler provides a temperature-controlled
environment for testing.
See page 156
See page 194
154 155
Inhaler Testing Ancillaries
Our range of Breathing Simulators are designed to generate an inhalation and/ With Impactor and Mixing Inlet (APSD)
or exhalation profile that mimics that of a human subject for more clinically Improving IVIVCs for nasal products Improving IVIVCs for nasal products
representative testing.
Volume Volume Volume
Replacing the fixed flow rate normally used for breathing simulators to measure the effects of different 0 to 800 mL 0 - 155 mL 0 - 900 mL 0 to 5000 mL
regulatory testing with a breathing profile has become breathing profiles, flow rates and breathing techniques
Patient Profile Suitability Patient Profile Suitability Patient Profile Suitability
routine in orally inhaled product (OIP) assessment, during product development.
Neonate/Infant ✓ Neonate/Infant ✓ Neonate/Infant ✗
with more and more laboratories turning to the use of
Child ✓ Child ✓ Child ✗
Adult ✓ Adult ✓ Adult ✓
Their use has two major applications:
21 CFR Part 11 Compliant 21 CFR Part 11 Compliant 21 CFR Part 11 Compliant
✗ ✓ ✓
156 157
Inhaler Testing Ancillaries
Key Features:
Breathing Simulator
BRS 100i
158 159
Inhaler Testing Ancillaries
Angle Adapter
Used to angle the device to a position representative of in vivo usage.
160 161
Inhaler Testing Ancillaries
Key Features:
Breathing Simulator
BRS 200i
For inhalation-only Inlet/outlet port for Intuitive 10.1 inch Easily import/export
Improved accuracy for profiles, the exhaust connection to the touchscreen control with methods and reports
Extensive data port diverts air directly DUSA, Filter Holder and icon-based menu structure
output options infant and neonate out of the exhaust, Mixing Inlet simplifies operation
profile volume instead of back through and clearly displays test
the device parameters throughout run
requirements
TOP
TIP For VHCs, simulate uncoordinated product use by starting the breathing profile
on the exhalation portion of the profile
162 163
Inhaler Testing Ancillaries
4 Approve methods
Main run test screen Main run test screen
5 Assign user roles, modify system administration settings
(ready to test) (test in progress)
6 Unrestricted access to all functions
With password-protected
user logins, each test run is
date and time stamped and
attributable to that user,
providing a clear audit trail.
User login screen Assigning user access level Volume/piston selection Settings menu
Choose from one of the Import a defined breath pattern Frequency 6 - 60 bpm
pre-set methods Configure their own from an external source
I:E Ratio Variable
RS-232
3 x USB A (for import/export of methods and connection with a USB keyboard or mouse)
Ethernet - for computer networking
Connectivity Temperature/Humidity Sensor port
RUN IN - for MDI Actuation Sensor or Footswitch
RUN OUT - to trigger activation of other connected electronic devices
164 165
Inhaler Testing Ancillaries
3 standard reports are available; Method Report, Run Qualification & Maintenance Ph. Eur. 2.9.44 USP <1601> and ISO 27427:2013
Report and Audit Report.
• Calibration certificate of compliance to Ph. Eur./USP compliant <1602> compliant compliant
1) Method Report and 2) Run Report both report the
provided as standard
following parameters:
• Comprehensive IQ/OQ/PQ documentation packages
• Waveform • Cycles
and toolkits available
• Volume (mL) • Cycle Duration (s)
• Frequency (bpm) • Test Duration (s) • Qualification Kit available 21 CFR Part 11 Extensive data Touchscreen user
• I:E Ratio • Max. Flow (L/Min) • Extended Warranty available compliant output options interface
• Start Delay (s) • Max. Acceleration (L/Min/Min)
• Inhalation Duration (s) • Cylinder Size (mL)
Breathing Simulator: BRS 200i
• Inhalation Delay (s) • Method creation information
• Exhalation Duration (s) (e.g. Status, Last Modified By) - Cat. No. Description Powerful drive system for
• Exhalation Delay (s) Method Report only Stores and
9176 Breathing Simulator Model BRS 200i generating challenging
• Start with: Inhalation/ • Last Run by (e.g. User, Last Run 1016 BRS 200i/300i Extended Warranty - 1 year recalls methods
profiles
Exhalation Date) - Run Report only 1017 BRS 200i/300i Extended Warranty - 2 years
166 167
Inhaler Testing Ancillaries
4 Approve methods
For inhalation-only profiles, the Inlet/outlet port for Intuitive 10.1 inch Easily import/export
exhaust port diverts air directly connection to the DUSA touchscreen control with methods and reports
out of the exhaust, instead of or Mixing Inlet icon-based menu structure
back through the device simplifies operation
and clearly displays test
parameters throughout run
TOP
TIP
For VHCs, simulate uncoordinated product use by starting the breathing profile
on the exhalation portion of the profile.
168 169
Inhaler Testing Ancillaries
Main run test screen Main run test screen Settings menu
(ready to test) (test in progress)
Reporting
BRS 300i: Technical Specifications
Extensive data output options are available as 3 x USB A 2 x Ethernet
standard, including direct reporting to a PC and
Volume 0 - 5000mL (500 - 5000 mL certified)
export to a USB memory stick.
Frequency 6 - 60 bpm Qualification & Maintenance
3 standard reports are available; Method Report, Run
I:E Ratio Variable Report and Audit Report. • Calibration certificate provided as standard
1) Method Report and 2) Run Report both report the • Comprehensive IQ/OQ/PQ documentation packages
Waveforms Sinusoidal, square, triangular, user-defined (flow vs time)
following parameters: and toolkits available
Profiles Inhalation and/or exhalation • Qualification Kit available
• Waveform • Cycles
Start Start on inhalation or exhalation stroke • Extended Warranty available
• Volume (mL) • Cycle Duration (s)
• Frequency (bpm) • Test Duration (s)
User Interface 10.1 inch, capacitive colour touchscreen
• I:E Ratio • Max. Flow (L/Min)
• Start Delay (s) • Max. Acceleration (L/Min/Min) Breathing Simulator BRS 300i
RS-232 • Inhalation Duration (s) • Cylinder Size (mL)
3 x USB A (for import/export of methods and connection with a USB keyboard or mouse) • Inhalation Delay (s) • Method creation information Cat. No. Description
Ethernet - for computer networking
• Exhalation Duration (s) (e.g. Status, Last Modified By) - 9186 Breathing Simulator Model BRS 300i
Connectivity Temperature/Humidity Sensor port 1016 BRS 200i/300i Extended Warranty - 1 year
• Exhalation Delay (s) Method Report only
RUN IN - for MDI Actuation Sensor or Footswitch 1017 BRS 200i/300i Extended Warranty - 2 years
• Start with: Inhalation/ • Last Run by (e.g. User, Last Run
RUN OUT - to trigger activation of other connected electronic devices
Exhalation Date) - Run Report only
Accessories
3) Audit report
8976 Temperature and Relative Humidity Sensor
All data changes reported with a date and 8797 MDI Actuation Sensor
time stamp attributable per user. 8791 Footswitch
9109 Real-Time Breath Profile Verification Chamber
9117 IQ/OQ Documentation for BRS 100i/200i/300i
9105 Qualification Kit for BRS 100i/200i/300i
9107 Re-calibration of BRS 100i/200i/300i Qualification Kit
9109 Real-Time Breath Profile Verification Chamber
170 171
Inhaler Testing Ancillaries
Timer
DPIs
In the case of DPIs, flow control is particularly The testing of DPIs is further complicated by the fact
important. Since most DPIs are classified as “passive” that devices vary in terms of their resistance to flow i.e.
devices (i.e. they rely solely on the patient’s inspiration some require more effort to inhale through than others.
to operate), variations in flow rate can significantly
Setting the flow rate for the testing of DPIs is more
affect device performance. It is therefore a regulatory
complex than for other types of OINDP. There are three
requirement that critical flow conditions are applied
Ancillaries during testing.
variables which need to be established to determine
the breath profile for DPI testing:
Flow Controllers Flow Rate (Q) Inspiration Volume Critical Flow Control
Flow rate and volume of air control are crucial when it comes to the DDU testing and 1. Flow Rate (Q)
APSD measurement of OINDPs. The use of an appropriate flow controller is vital to The in vivo strength and duration of the user’s Using a flow control valve, it is then a simple matter
comply with the regulatory requirements and streamline the testing, and when creating inspiration is broadly replicated by the flow rate to adjust the flow rate from the vacuum pump to
used and the duration of testing. produce the required pressure drop of 4 kPa and
specific methods which are easy to follow and transfer as required. then, by replacing the inhaler with a suitable flow
To establish the correct flow rate the flow rate meter, to measure the flow rate, Q, required to
The Ph. Eur. and USP require that test flow rate is controlled to within +/-5% of the specified value. This requirement required must first be established to produce a
can be met by selecting an appropriate flow control ancillary. produce this pressure drop.
pressure drop comparable with that found at the
mouth of the user in vivo when using the particular
inhaler being studied.
MDIs, MDIs with a Spacer/VHC, BAIs, Nebulisers, ADIs, Nasal Sprays
Both the [Link]. and USP suggest a pressure drop Flow
& Nasal Aerosols over the inhaler of 4 kPa as broadly representative
Regulatory requirements for these OINDPs call for the control of: of the pressure drop generated during inhalation by
patients using DPIs.
- air flow rate - to a defined constant flow rate or to apply defined breathing profiles. See 156.
- total air volume The pressure drop created by drawing air through
ΔP = 4 kPa
- delay/synchronisation to begin sampling at a defined time. an inhaler can be determined by measuring the
absolute pressure downstream of the inhaler
mouthpiece and comparing this directly with
* � 100 kPa (atmosphere)
It is this Flow Rate Q, that the pharmacopoeias state should be used for DDU testing and APSD measurement.
The only exception to this criterion is that if the flow required to produce a 4 kPa pressure drop is >100 L/min, as for example in the case
of particularly low resistance inhalers, then 100 L/min should be used.
172 173
Inhaler Testing Ancillaries
Conforming to the Ph. Eur. and USP specifications for section), our Flow Controllers have become the
2. Inspiration Volume a system that controls the key variables impacting the industry-standard for both DDU and APSD applications.
TOP
Once the flow rate (Q) has been established, it is now necessary TIP test conditions for DPIs (as described in the previous
to control the volume of air drawn through the inhaler during testing
By using a timer to control the time
to the 2 or 4 litres per simulated inhalation required by
that the solenoid valve is open, it is
the pharmacopoeias/regulators.
TOP
TIP 4 litres is considered to be the normal forced inhalation capacity of an average sized male weighing approx. 70kg. In
practice, it is not uncommon to widen the scope of the test parameters to cover a broader target patient population,
such as geriatrics and paediatrics, as well as those already suffering from pulmonary problems, including typical use and
unintentional misuse conditions.
DPI N Y
3. Critical Flow Control
Once the parameters to control the strength and An easy way to validate flow rate stability is to
duration of the simulated breathing cycle have been ensure that critical (sonic) flow occurs in the flow
Nebuliser Y Y
established, there is one final issue to be considered control valve. This can be confirmed by simply
– flow rate stability. measuring the absolute pressure at a point on either
side of the valve.
Ensuring stable flow throughout the test is critical ADI Y Y
to the testing of DPIs, since, as passive devices, they Providing that the pressure downstream of the valve
can be sensitive to small changes in flow rate. is less than half of the upstream pressure i.e. that the
ratio P3/P2 ≤ 0.5 then critical (sonic) flow is assured Nasal Spray Y Y
and the flow rate can be assumed to be stable.
Nasal Powder N Y
DUSA
Vacuum Pump Critical Flow Collection Vacuum Pump Critical Flow Cascade
Controller Tube Controller Impactor
174 175
Inhaler Testing Ancillaries
Key Features:
Interfaces
with DFM4
176 177
Inhaler Testing Ancillaries
178 179
Inhaler Testing Ancillaries
Key Features:
TOP
TIP
The TPK can also be used as a Breath Actuation Controller
(BAC) for testing MDIs with a spacer/VHC and BAIs in
accordance with [Link]. 0671 and USP Chapter <1602>.
180 181
Inhaler Testing Ancillaries
Guided test set up process Test set-up report Target v Actual test parameters
(before test run)
Footswitch
Enabling precise synchronisation of device actuation with the onset
of flow, the Footswitch connects directly to the TPK 100i.
Alternatively, an MDI Actuation Sensor can be used for
Leak test screen Device resistance measurement Settings menu synchronisation of MDI actuation and the onset of flow.
Printer
Connect a compatible printer via the USB connection in the BAC 100i
unit for instant test run reports.
Guided calibration process Flow method screen Test settings
182 183
Inhaler Testing Ancillaries
Ancillaries
Flow Meters
Air flow control is critical in the DDU and APSD testing of OINDPs. For many inhaled Application DFM4 DFM 2000
products, air flow triggers or drives aerosolisation of the formulation and it can therefore
have a significant effect on both delivered dose and APSD. Equally importantly, air flow Pharmacopoeial Y Y
impacts the performance of the test apparatus, notably cascade impactors which are
designed to function at a constant air flow rate.
IVIVC N Y
In addition, for some devices, especially DPIs, the air flow through the device provides the motive force for dose
delivery; indeed, some breath-actuated/operated devices trigger only when the flow rate through them exceeds
a certain value.
A constant, repeatable flow rate is required throughout Air flow rate has a direct influence on the
testing to ensure conformance with the regulatory aerodynamic performance of cascade impactors.
requirements and pharmacopoeial specifications. The jet-to-plate distances on most commonly used In-line Flow N Y
impactors are fixed. Therefore, as long as the nozzle
diameters remain within defined tolerances and there
are no leaks in the system, the cutoff diameter of
any given stage is directly related to the volumetric
flow rate of air passing through it. A change in flow
rate results in a change in the aerodynamic particle
size characteristics of the stage or stages concerned
altering the measured APSD.
184 185
Inhaler Testing Ancillaries
Volumetric Mode:
Calculation of flow
Low flow resistance
rate based on live T/P
conditions
Standard Mode:
Direct measurement of Calculation of flow rate
Clear digital display Can also be Data connectivity
volumetric flow used in-line based on preset T/P
conditions
Technical Specifications Qualification & Maintenance Technical Specifications Qualification & Maintenance
Operation Principle Differential Pressure (Venturi)
• Calibration certificate of compliance Operation Principle Hot Wire Mass Flow
• Calibration certificate of compliance
to Ph. Eur./USP provided as standard to Ph. Eur./USP provided as standard
Flow Rate Range 10 – 105 L/min Flow Rate Range 0 – 200 L/min
Resolution 0.1 L/min Resolution 0.1 L/min between 90 and 200 L/min
Flow Meter DFM4 Flow Meter DFM 2000
Accuracy +/- 2% of reading or 0.7 L/min (whichever greater) Accuracy +/- 2% of reading
Cat. No. Description Cat. No. Description
Flow Resistance Low flow resistance (1.0 kPa @ 100 L/min) 8004 Flow Meter Model DFM4 8764 Flow Meter Model DFM 2000
Accurate calculation from in-built
Volumetric Flow Calculation
T & P sensors
Volumetric Flow Calculation Direct measurement of volumetric flow Accessories Accessories
Inlet Filter No inlet filter required Inlet filter required in un-filtered
5238 Universal Flow Meter Adapter Inlet Filter 5238 Universal Flow Meter Adapter
laboratory environment
8061 Re-calibration Certificate for DFM4 8765 Re-calibration Certificate for DFM 2000
Interface to external devices, such as
8005 Calibration Kit for DFM4
Connectivity - Breath Actuation Controller BAC 100i Interface to external devices, such as
8006 Re-calibration of DFM4 Calibration Kit
- Critical Flow Controller TPK 100i Connectivity - Breath Actuation Controller BAC 100i
- Critical Flow Controller TPK 100i
Reporting Flow rate and calibrate date via RS-232
Reporting Flow rate & calibrate date via RS-232
Calibrations Calibration kit available for user calibrations
Calibrations Factory calibrations only
186 187
Inhaler Testing Ancillaries
MDI Y Y Y Y
Ancillaries
We offer vacuum pumps specifically designed for use in the testing of MDIs, DPIs, DPI sonic flow with
N N Y Y
nebulisers and nasal products in accordance with the specifications laid down NGI @ > 80 L/Min
Nebuliser Y Y Y Y
ADI Y Y Y Y
Nasal Spray Y Y Y Y
Nasal Aerosol Y Y Y Y
Nasal Powder N Y Y Y
188 189
Inhaler Testing Ancillaries
Technical Specifications Qualification & Maintenance Technical Specifications Qualification & Maintenance
Type Rotary Vane • Included in IQ/OQ Documentation for 1 x HCP6 2 x HCP6 • Included in IQ/OQ Documentation for
Inhaler Testing Systems - see page 309 Inhaler Testing Systems - see page 309
Lubrication Type Dry Type Rotary Vane Rotary Vane
• Extended Warranty available • Extended Warranty available
Max. Flow in L/min (unrestricted) 133 Lubrication Type Dry Dry
Max. Sonic Flow through NGI N/A Max. Flow in L/min (unrestricted) 416 833
LCP6 Low Capacity Pump HCP6 High Capacity Pump
Max. Vacuum Level <15 kPa Max. Sonic Flow through NGI 80 100
Cat. No. Description Cat. No. Description
Applications: Nasal Yes Max. Vacuum Level <15 kPa <15 kPa
7923 Low Capacity Pump Model LCP6 7921 High Capacity Pump Model HCP6
Nebulisers Yes 1022 LCP6 Pump Extended Warranty - 1 year Applications: Nasal Yes Yes 1024 HCP6 Pump Extended Warranty - 1 year
1023 LCP6 Pump Extended Warranty - 2 years 1025 HCP6 Pump Extended Warranty - 2 years
MDIs Yes Nebulisers Yes Yes
DPIs No MDIs Yes Yes Accessories
Accessories
Routine Maintenance None DPIs Yes No
7905 Overhaul Kit for HCP6
Dimensions (w x d x h) 270 x 335 x 280 mm 7904 Overhaul Kit for LCP6 Routine Maintenance None None
Weight (kg) 18.4 kg Dimensions (w x d x h) 322 x 580 x 390 mm 750 x 580 x 390 mm
Weight (kg) 45 90
190 191
Inhaler Testing Ancillaries
Advanced
cooling Advanced sound
insulation
Quick-Rrelease
Connector
Oil lubricated
included as rotary vane
standard
192 193
Inhaler Testing Ancillaries
Key Features:
Built-in light for Easy access via
high visibility large front and
rear doors
Twin side
access ports for
the nebuliser
(and mixing
inlet if used)
Double-glazed
panels ensure
high energy
efficiency
Comfortably
accommodates
NGI in open or
closed position
Additional space
for cooling of other
components, such as
collection cups meaning
Ancillaries Benchtop unit multiple test can occur
NGI Cooler
in quick succession
Exacerbated evaporation caused by the thermal mass of the NGI may be an NGI Cooler Accessories Qualification & Maintenance
issue for devices such as nebulisers that deliver the drug as an aerolised solution. • Comprehensive IQ/OQ/PQ documentation
Loss of solvent reduces droplet size, producing artificially low particle size NGI Cooler Stand
packages and toolkits available
measurements and compromises the integrity of APSD data. Saving precious benchtop space, • Extended Warranty available
the NGI Cooler Stand raises the
The NGI Cooler is designed to support testing in a temperature-controlled environment, NGI Cooler to eye level making
cooling the impactor to 5°C to overcome the issue of droplet size change due to evaporation. operation convenient for the user, NGI Cooler
creating an area underneath to
Cat. No. Description
place any additional ancillaries
5009 NGI Cooler
and components. 1046 NGI Cooler Extended Warranty - 1 year
Ph. Eur. and Quiet
1047 NGI Cooler Extended Warranty - 2 years
USP compliant operation
Accessories
NGI Cooler: Technical Specifications
9114 NGI Cooler Stand for BRS 200i
Ph. Eur. 2.9.44 5011 NGI Cooler Qualification Documentation
Precise temperature
5012 NGI Cooler Qualification Tools
Pharmacopoeial Compliance USP <1601>
control 5013 Re-calibration of NGI Cooler
EPAG recommended
Qualification Tools
Temperature Range 0 °C and ambient (typically 5 °C to 10 °C)
194 195
Inhaler Testing Ancillaries
Inhaler Testing
Workstation (ITW)
WSC2: Waste Shot Collector Mount
The hub of an inhaler testing system, the ITW is a modular workstation designed Quick-release
to aid handling and manipulation of the various pieces of test apparatus and connectors ITW for WSC2 with Switching Valve
196 197
Inhaler Testing Ancillaries
DFM 2000 Flow Meter Holder A variety of tubing is available to provide connections Quick-Release Connectors are provided as standard
between the various components making up the inhaler with various pieces of equipment. Additional connectors
Holder for USP Induction Port
testing system. The 3 mm tubing is designed to provide can be purchased if required in two sizes, 13 mm and 16
the connection between the DUSA for DPIs and Critical mm designed for use with 10 mm i.d. and 16 mm i.d.
Flow Controller. tubing respectively.
ITW attachments for
APSD measurement
Tubing Quick-Release Connectors
Multi-Stage Liquid
Impinger (MSLI)
198 199
Inhaler Testing Ancillaries
Ancillaries
Key Features:
Glass Expansion Chambers
The majority of nasal products are designed to generate droplets/particles with a mass
median aerodynamic diameter (MMAD) of greater than 10 to 20 microns. This is to increase
nasal deposition and minimise deposition in the lungs.
However, most sprays deliver a proportion (typically Cascade impactors are designed to capture particles in
<5%) of fine droplets in the <10 micron range. It is the range 0 to 10 microns and are widely used for
important to quantify this Fine Particle Dose (FPD) this application. Representative testing: entry
since it can penetrate beyond the nasal tract and port at 30° to outlet port for
insertion of nasal device
into the lower respiratory tract or lungs, which may
be undesirable.
ACI and NGI adapters
available for airtight
connection between outlet
Broad characterisation of nasal drug particle deposition within respiratory system port of expansion chamber TOP
and impactor TIP After validation, it may be
appropriate to use a reduced
impactor stack (e.g. Stage 0
Particle D > 10 microns (Internal Passageways) = >9 microns, Stage 2 = 4.7 to
Nasal cavity 9 microns, Stage F = 0.0 – 4.7
microns of an ACI at 28.3
Mouth
L/min).
Particle D = 5 - 10 microns (Upper Respiratory Tract)
Pharynx
200 201
Inhaler Testing Ancillaries
Mouthpiece &
8950 1000 mL Glass Expansion Chamber
8951 2000 mL Glass Expansion Chamber
8952 5000 mL Glass Expansion Chamber
8953 Volume Verification Certificate for Expansion Chamber
8954
5217
8961
5212
Adapter & Clamp for ACI/FSA*
Adapter & Clamp for NGI/FSI*
Set of 10 O-Rings for Expansion Chamber Adapter
‘Quick Clamp’ for ACI
Nosepiece Adapters
8955 Benchtop Holder for Glass Expansion Chamber Ensure a proper seal is maintained between the device under test and the sampling
apparatus with our range of Mouthpiece and Nosepiece Adapters.
* Please specify Aluminium (A), 316 Stainless Steel (S) or Titanium (T) when placing your order.
Specially moulded from high quality silicone rubber to The adapters are generally transferable between
ensure superior performance, adapters are available for different product test systems, however, there are
the more common devices on the market, or can be cases where the inlet diameters may differ between
custom-made for your specific device type. apparatus. Please specify the intended testing system
when ordering to ensure the correct size adapter
is supplied.
202 203
Inhaler Testing Ancillaries
Mouthpiece Adapters
Suffix the letter below to the Cat. No. for listed Mouthpiece Adapters, e.g. 5003C Mouthpiece Adapters
C Easyhaler® D Cyclohaler® E Handihaler® F Diskus® Cat. No. Description
G Novolizer® H Rotahaler® I Turbuhaler® J Diskhaler® 5003 Custom Mouthpiece Adapter for Induction Port, DUSA, WSC2, Filter Holder and Child Alberta Idealised Throat
5004 Tooling Charge for Custom Mouthpiece Adapter
K Respimat® L Evohaler® M Pari LC Plus® N Trudell AeroChamber® 5237 Custom Mouthpiece Adapter for Glass Twin Impinger and FP Induction Port
8515 Custom Mouthpiece Adapter for Adult Alberta Idealised Throat and Albuterol SCA
O Tobi Podhaler® P Ellipta® Q Rapihaler® R Nexthaler®
9013 Custom Mouthpiece Adapter for PTT 1000
S Qvar® Autohaler® T K-haler® U Airomir® Inhaler V PowdAir Plus®
Accessories
204 205
Inhaler Testing AerodynamicSoftware
Particle
Size Distribution
Inhalytix™
USP Chapter <601> and [Link]. Chapter 2.9.18 and draft USP Chapter <1604> System Characteristics
specify various types of multi-stage cascade impactor that can be used for Quick and easy to install, Inhalytix™ is 21 CFR
measuring the drug-specific aerodynamic particle size distribution (APSD) of part 11 compliant, enabling the creation of users,
orally inhaled and nasal drug products (OINDPs). assignment of multiple roles (typically admin,
supervisor and analyst) and access to audit logs,
This process involves quantitative recovery and metrics can be derived that are used to characterise assisting in data monitoring and ensuring data
chemical analysis of the size-fractionated aerosol, the APSD, in accordance with pharmacopoeial integrity. The software will operate on Windows 7, 8
typically by High Pressure Liquid Chromatography specifications and various FDA and EMA guidance. and 10 operating systems.
(HPLC). From the resulting assay a number of important
Inhalytix™ data analysis software is a flexible and fully the software will accept data from standard and Equipment Types
validated solution for the entry, analysis and reporting customised cascade impactors, including the Andersen
The software is pre-populated with the most
of the APSD of drug output from all OINDPs. It also Cascade Impactor (ACI), Next Generation Impactor (NGI),
commonly used impactor types for immediate
serves as a database for laboratory-based cascade Fast Screening Impactor (FSI), Fast Screening Andersen
use. However, it is not uncommon for custom
impactor inventory and provides for the setting up and (FSA), Glass Twin Impinger (GTI)
versions of cascade impactors to be used in
running of detailed test methods. User-configurable, and Multi-Stage Liquid Impinger (MSLI).
some laboratories. In these circumstances,
users can generate bespoke impactor types
that can then be stored and recalled for use
later. This function may, for example, allow a
Licensing user to add or remove certain stages from an
Inhalytix™ is available as a thee user licence software package, based on named impactor or add special components to the
users that can be added or removed by the system administrator. The software software, such as modified induction ports.
is available via PC, server and cloud-based installations, with digital licence keys
supplied by email. Additional packages of three users are available and can be
added to the system at any time.
206 207
Inhaler Testing AerodynamicSoftware
Particle
Size Distribution
Equipment Inventory
Keeping track of equipment inventory and associating The software allows a high degree
it with the corresponding inhaler testing data can be a of customisation, including both
burden. For this reason, the Inhalytix™ equipment asset a “Summary” or “Detailed” report
library allows users to keep their equipment databased template and toggles to turn on or
and include equipment-specific data in their testing off the reporting of a broad range
reports. Not only does this allow users to keep track of metrics. Company logos can be
of equipment, it ensures full traceability by keeping added to the report header
comprehensive records of which specific pieces of if required.
equipment were used for each test. Furthermore, the
software provides the user with the option to enter
impactor-specific mensuration data, allowing the
precise calculation of stage cut-off diameters, thereby
enhancing the precision and accuracy of test results.
The software will also notify users if an impactor is due
for stage mensuration.
2. Equipment
Configuration The equipment configuration screen
Testing of different drug products requires different methods to be allows users to generate specific
in place, different equipment to be used and different metrics to be combinations of impactor/impinger
calculated. This configuration takes place in three easy steps: and components to match the
equipment configuration described
Reports • Equipment • Methods in the testing protocol. Users simply
drag and drop the impactor and
components of their choice into the
equipment configurator. This, for
1. Reports
example, could see the combination
The Reports configuration screen allows users to create tailored report of an NGI, with external filter holder,
templates, which are then stored and can be paired with different test NGI preseparator, NGI induction port,
methods, allowing data to be reported as required. mouthpiece adapter and inhaler.
The software automatically sorts
the components into the correct
order and ensures that only viable
combinations can be created.
208 209
Inhaler Testing AerodynamicSoftware
Particle
Size Distribution
1. Prepare
3. Methods To prepare for a test, users are required to recall the test method relating to the product to be tested. During this step,
users will have the opportunity to enter test specific information, including the number of runs to be performed.
Creating a test method allows the user to combine delivered dose (when testing MDIs, DPIs, ADIs
detailed product information, such as drug etc.) or drug substance delivery rate (when testing
components and device details, with equipment and nebulisers) is recorded. Configuring the product
report configurations. Users have the opportunity to specific method is the final step before a user can
define for example stage groupings and fine particle run a test and analyse their results.
dose (FPD) specifications and to select whether
Tests
Once the necessary report, equipment and
test method configurations are in place,
the user is ready to enter the data and
complete the analysis. This function can
be found under the ‘Tests’ tab. Tests are
completed in three steps:
2. Execute
Prepare • Execute • Analyse
The user then executes the test
All tests are databased and their current by entering the number of doses
status can be monitored to see if they are actuated and drug deposition values
at the prepared stage, whether results have for each stage of the impactor, as
been entered or whether they are complete. well as any additional components
included in the equipment
configuration. This process is
then repeated for all additional
runs. Alternatively, data can be
automatically imported from a CSV
or XLSX file.
All values are easily displayed in a
scrollable table and can be edited
at any point prior to analysis, for
example when importing data from
HPLC software or exporting data for
report writing.
210 211
Inhaler Testing AerodynamicSoftware
Particle
Size Distribution
3. Analyse
Once all data has been entered or imported the • Graphs – allows viewing of log-probit plot, drug
software analyses the data and presents it to the user deposition (by impactor stage/component) and
in the form of: cumulative drug distribution for each run. Also allows
• Results Summary – provides all the key metrics for all the comparison of up to 3 runs from the same
test runs in a scrollable table for immediate review. test or other tests, so long as the same equipment
configuration and data analysis specifications have
• Groups Results (where used) - displays the drug
been set previously.
fractions for each stage or size grouping defined in
the method. • Reports – allows viewing and printing of standard and
customised reports.
Inhalytix
Summary of Key Features
• Standardised approach to the analysis of impactor data Cat. No. Description
8260C Inhalytix Data Analysis Software
• Ph. Eur. 2.9.18 and draft USP <1604> compliant
(3 user licences) - Cloud
• 21 CFR Part 11 compliant 8260P Inhalytix Data Analysis Software
• Fully validated with in-built auto-validation protocols (1 user licence) - PC
8260S Inhalytix Data Analysis Software
• Supports PC, server and cloud-based installations
(3 user licences) - Server
• Equipment inventory and test-related database 8261 Additional 3 User Licences for Inhalytix
• Impactor-specific mensuration data log (Cloud & Server)
• Bespoke configurations, methods and reports 8263 Annual Support and Upgrade
Package (per user)
• Data import and export capability for use with HPLC software
• Quick 3-step results analysis: Prepare - Execute - Analyse
• Runs and/or Tests comparison capabilities
212 213
Inhaler Testing Aerodynamic
ImprovingParticle
IVIVCs
Size Distribution
Making a relatively small investment in systems that enhance the clinical realism of standard
Patient
pharmacopoeial in-vitro test set-ups for the delivered dose uniformity (DDU) testing and Flow Rate & Volume
aerodynamic particle size distribution (APSD) measurement may help bridge the gap between data
collected during quality control (QC) testing and in vivo performance helping to accelerate and
improve research and development (R&D).
Dissolution
USP/[Link]. Methods Testing
Clinic (PK/PD)
Efficacy Compliance
DDU
Realistic
FPD*
Breathing
Profiles Morphology
Particle
Improving Dispersion
IVIVCs
Formulation Device
Resistance
Realistic Throat
& Nasal Models Facemask
IVIVCs - Bridging the gap Testing
*Fine Particle Dose
Cold Freon® In this environment, accuracy and sensitivity alone do not maximise the utility of in
Effect
vitro testing. Due to the complex interactions between formulation and device and
the impact of patient-to-patient variability, identifying robust relationships between
product characteristics and clinical efficacy can be challenging - very few good IVIVCs
exist for OINDPs.
214 215
Inhaler Testing Aerodynamic
ImprovingParticle
IVIVCs
Size Distribution
For OINDPs it is possible to identify Critical Quality Improving the clinical relevance of in vitro tests and in Dissolution Testing
attributes (CQAs) relating to the Patient, Device silico models is an important area of focus for both the
In vitro dissolution testing is becoming more widely used for optimising efficacy
and Formulation. The impact of variability in all of industry and for regulators, largely because of demand
during drug development, ensuring batch-to-batch consistency and in some cases
these parameters is necessarily a focus in product for generic OINDPs. This is reflected in the recent
to predict bioavailability in vivo and and help demonstrate BE.
development and more easily studied if the clinical investments made by the FDA for the identification,
development and validation of clinically relevant in vitro See page 230
realism of in vitro test methods is improved.
testing methods.
Facemask Testing
Beclomethasone Dipropionate Inhalation In situations where the user lacks the capability of using a mouthpiece (e.g. small
Aerosol Draft Guidance (2019) children, the elderly), it is commonplace to use a facemask for inhaled drug
The FDA has released product specific draft delivery. The amount of inhaled drug available to the patient is dependent upon
Throat Geometry Throat Geometry
Breath Profile Breath Profile
guidance highlighting the use of novel in vitro testing the interface between the facemask and the patient and must be rigorously
Patient Delivered Dose = Delivered Dose
Aerodynamic Particle Aerodynamic Particle approaches for the assessment of Beclomethasone quantified under representative conditions.
CQAs Size Distribution Size Distribution
Dipropionate aerosol as an alternate to a comparative See page 236
clinical endpoint BE study.
Flow Resistance Flow Resistance
Dose delivery method Dose delivery method
The guidance lists additional supportive in vitro
Device (e.g. blister) = (e.g. blister)
CQAs
Formulation dispersion
method (CFD)
Formulation dispersion
method (CFD)
studies that can be conducted to support and Morphology
enhance clinical realism and improve IVIVCs.
Profiling the morphological properties e.g. particle size and shape of an inhaled
These studies include the use of representative
drug formulation may be useful for comparative assessment against a reference
Dose Dose mouth-throat models and breathing profiles; the
Formulation Dissolution rate
=
Dissolution rate
characterisation of aerosol velocity profiles and
drug product notably to assess aerosolisation performance and the extent of
Morphology/particle Morphology/particle
CQAs interaction interaction
evaporation rate; drug dissolution testing; and a full deagglomeration. See page 246
assessment of particle morphology.
216 217
Inhaler Testing Improving
Ancillaries
IVIVCs
TOP
TIP Using data acquired from the clinical use of spirometers, breathing simulators are used to generate representative
breathing profiles, offering the chance to more closely assess how factors such as the strength of inhalation and lung
capacity can affect the performance for passive devices such as DPIs.
See page 156 for more information about our range of Breathing Simulators.
Mixing Inlet
Applying more representative breathing profiles using a breathing simulator during APSD measurement is
complicated by two key issues:
Improving IVIVCs
2 the test flow rate applied to the inhaler may need to be lower than the minimum calibrated flow rate
of the impactor. For example in paediatric studies a representative flow rate may be 10 L/min but the
Two factors that have been identified as being critical to improving the clinical impactor may have a minimum calibrated operating flow rate of 28.3 L/min.
relevance of DDU testing and APSD measurement are:
Our Mixing Inlets are designed to allow the cascade impactor to operate
Realistic Breathing Profiles Realistic Throat and Nasal Models
at a constant flow rate, whilst permitting a lower fixed or variable rate
Replacing the existing constant In the case of APSD measurement, to pass through the inhaler. Positioned between the induction port/
air flow rate conditions used in replacing the existing [Link]./USP throat/nasal inlet and cascade impactor, Mixing Inlets decouple the flow
testing with breathing profiles Induction Port with an age-appropriate rate through the device from the air flow drawn through the impactor,
more representative of the mouth/throat or nasal model with a enabling more representative testing.
conditions applied by specific more realistic human-like geometry.
patient populations.
Mixing Inlet (NGI), Mixing Inlet (ACI)
Mixing Inlet
218 219
Inhaler Testing Improving
Ancillaries
IVIVCs
The throats and nasal models we offer were developed from extensive research into typical patient populations including information
provided by CT and MRI scans, direct observation of living subjects and data in the archival literature. Each has a standardised internal
geometry more representative of in vivo physiology than a standard induction port and suitable for a range of patient profiles. More
information and references are available on request.
Mouthpiece adapter
interface at inlet
220 221
Inhaler Testing Improving
Ancillaries
IVIVCs
Key Features:
Quick-release clips Idealised geometry Smooth, uniform internal geometry
make internal coating representing a range for more representative testing
and drug recovery of patient groups to allow for coating and to ensure
quick and simple inter-nasal passageway uniformity F
Olfactory region
Turbinates
Seals ensure
leak-free testing
Nasopharynx
Vestibule
(Nostril)
Chemically Manufactured from aluminium
compatible for durability and to ensure
with a range of dimensional reproducibility
solvents
IVIVC System for DDU Testing of MDIs
Alberta
Alberta Idealised
Idealised Nasal
Nasal Inlet (Open)Inlet (AINI) A
Dose Uniformity Sampling
B Inhaler Testing C Mouthpiece Adapter
Apparatus (DUSA) for MDIs workstation (ITW)
DUSA Holder
Cat. No. Description
D E Alternative dose F Alternative dose collection
8540 Alberta Idealised Nasal Inlet (AINI) for NGI/FSI Breathing Simulator
collection device: device: Filter Holder
8541 Alberta Idealised Nasal Inlet (AINI) for ACI/FSA DUSA for DPIs
8326 ACI to NGI Outlet Adapter
Different outlet adapters are available for a
8327 NGI to ACI Outlet Adapter range of applications
8543 Alberta Idealised Nasal Inlet Leak Test Cap and Inlet Adapter
222 223
Inhaler Testing Improving
Ancillaries
IVIVCs
Required for:
IVIVC System for APSD Measurement of DPIs
DUSA for DPIs and Nasal Powders. See page 22.
Compressed Air Compressed Air Alberta Idealised Mouthpiece F Preseparator
A B C D E Mixing Inlet
Source Flow Controller Throat Adapter
Required for:
Cascade Breathing Critical Flow Flow
G H I J K Vacuum Pump
Impactor Simulator Controller Meter
Filter Holder for MDIs with Spacers/VHCs and Nebulisers. See page 25.
Required for:
A B C D E F G H I J K
Mouthpiece Adapters
Moulded from high quality silicone rubber, our Mouthpiece Adapters
guarantee an airtight seal between the inhaler under test and the
test apparatus.
Required for:
Nosepiece Adapters
Our Nosepiece Adapters interface the nasal device with the test system.
Required for:
IVIVC System for APSD Measurement of Nebulisers
See page 203 for further information
Breathing Compressed Mouthpiece
A B C D Induction Port E Mixing Inlet F Cascade Impactor
Simulator Air Source Adapter
224 225
Inhaler Testing Improving
Ancillaries
IVIVCs
Improving IVIVCs - APSD Measurement Test System Components: In addition to the Breathing Simulator, Mixing Inlet and a realistic throat/nasal model, the
following is needed to complete a fully-operational IVIVC test system for APSD measurement:
Breathing Simulator
Cascade Impactor
With an intuitive touchscreen interface for easy operation, our range
Forming the basis of most systems used to measure APSD, a choice of
of Breathing Simulators are designed to produce breath profiles across
cascade impactors is available depending on device type and application.
a range of ages (paediatric to geriatric) and patient conditions (mild to
See page 82 for further information about our range of Cascade Impactors.
severe lung impairment).
For further information about the range, see page 156. Required for:
Required for:
Vacuum Pump
Our Vacuum Pump range represents the latest in high performance,
low maintenance, technology and is specifically designed for use in
Mixing Inlet the testing of OINDPs. See page 188 for further information about our
Vacuum Pump range.
Decoupling the flow rate through the device from the air flow drawn
through the impactor, the Mixing Inlets are needed to enable the Required for:
cascade impactor to continue to operate at a constant flow rate, whilst
allowing a lower fixed or variable rate to pass through the inhaler.
Flow Meter
Required for:
Used for establishing accurate and consistent inlet flow rate during
testing, our range of Flow Meters measure and control flow within
method specification. See page 184 for further information about our
Alberta Idealised Nasal Inlet (AINI)
range of Flow Meters.
Mimicking nasal drug deposition behaviour in the nostril, turbinates,
olfacrtory region and nasopharynx, the AINI helps users to identify the Required for:
fraction of the drug absorbed via the target pathway and realistically
evaluate any unintended drug transit to the lungs.
NGI Cooler
Required for: Accommodating the NGI both open and closed, the NGI Cooler
maintains a temperature-controlled environment throughout testing.
Additional space allows for the cooling of extra sets of collection
cups, so that multiple tests can be undertaken in quick succession.
See page 194 for further information.
226 227
Inhaler Testing Improving
Ancillaries
IVIVCs
See page 195 for further information. • Companies should establish procedures to ensure the fitness for use of instruments
that generate data supporting product testing
Required for:
Copley provides a range of qualification documentation, services and tools to meet
these requirements.
See page 302 for further information.
Compressed Air Flow Controller
Designed to balance the steady state flow rate entering the impactor,
the Compressed Air Flow Controller ensures that the flow rate at the
inlet to the induction port is zero prior to starting the test. TOP
TIP
Vertus System interface with Breathing Simulator
Required for:
For the IVIVC testing of MDIs, nasal sprays and
nasal aerosols, interfacing the VertusII/Plus (see
page 270) with the Breathing Simulator Model BRS
300i enables full control of the device actuation
parameters (e.g. shaking, actuation force) allowing
Air Compressor for Mixing Inlet the fully automated application of patient
representative profiles. Users can create test
To provide supplementary air to the inlet port of the Mixing Inlet via the
methods that fully describe the patient population
Compressed Air Controller. the product is intended for and thus, create a
realistic testing method according to their needs.
Required for:
Improving IVIVCs
Mouthpiece Adapters
Cat. No. Description
Moulded from high quality silicone rubber, our Mouthpiece Adapters 8328A Mixing Inlet for ACI, FSA and MSLI (316 Stainless Steel)
guarantee an airtight seal between the inhaler under test and the 8326 ACI to NGI Outlet Adapter
test apparatus. 8327 NGI to ACI Inlet Adapter
8329A Mixing Inlet for NGI and FSI (316 Stainless Steel)
Required for: 8324 Set of 2 O-Rings for ACI Mixing Inlet
9160 Compressed Air Flow Controller for Mixing Inlet
9161 Compressed Air Inlet Manifold for Mixing Inlet
Nosepiece Adapters 9162 Compressed Air Inlet Manifold for Mixing Inlet & BRS 100i
9163 Compressed Air Inlet Manifold for Mixing Inlet & BRS 200i/300i
Our Nosepiece Adapters interface the nasal device with the test system. 9164 Air Compressor for Mixing Inlet
9165 Re-calibration of Compressed Air Flow Controller
9166 Maintenance Kit for Air Compressor
Required for:
228 229
Inhaler Testing Improving
Ancillaries
IVIVCs
We offer a range of equipment designed for particle selection, dose collection and dissolution testing, to help
analysts identify, segregate and assess the dissolution characteristics of inhaled drug products.
1. Particle Selection
or
2. Dose Collection
or
Dissolution Testing
NGI Dissolution Cups
3. Dissolution Testing
Due to the small size of inhaled drug particles and their typically highly soluble nature,
dissolution has always assumed to be very rapid at the site of action. However, the
dissolution of inhaled drugs is complicated by a number of issues and is becoming an
area of increasing interest for regulators. For example, there is concern that variability
between patient groups in the amount and composition of lung and nasal fluid may
affect drug uptake. It is important to highlight the value of inhaled dissolution as a BE
tool, with the potential to discriminate between formulations of the same drug(s).
Designing a standardised dissolution test method One of the main problems facing the developers Standard USP Dissolution Tester
relevant to the lungs is not easy because of the small of such methods is the identification and segregation of
amount of aqueous fluid involved and the presence that part of the total emitted dose actually reaching the
of endogenous surfactants. Currently, there are no target site (as opposed to the whole dose) in a
official dissolution test methods specifically for form readily adaptable to conventional dissolution
inhaled products. testing techniques.
The small amount of aqueous fluid and surfactant found in the lung make it extremely difficult to mimic inhaled dissolution
testing in vitro. Marques, Loebenberg and Almukainzi (2011) list five of the most simulated lung fluids in Table 11 of their article
‘Simulated Biological Fluids with Possible Application in Dissolution Testing’. Read it to find out more.
230 231
Inhaler Testing Improving
Ancillaries
IVIVCs
1 & 2. Particle Selection & Dose Collection Andersen Cascade Impactor (ACI)
Following a similar technique to that used for the NGI,
with the ACI the drug is instead captured directly onto
Next Generation Impactor (NGI) the membrane prior to analysis.
A modification of the standard NGI Collection Cup, the
1 A 76 mm polycarbonate membrane is applied to the
NGI Dissolution Cup and Membrane Holder enables collection plate prior to particle sizing
size-fractionated particles from an aerosol cloud to
2 Particle sizing is carried out in the conventional manner
be collected and tested using a conventional tablet
dissolution tester. 3 The membrane is inverted and sandwiched between the
glass and PTFE surfaces of the Watchglass/PTFE Assembly
NGI Dissolution Cups (traditionally used for transdermal patches). Watchglass/PTFE Assembly for use with ACI
1 Particle sizing is carried out in the conventional manner. NGI Dissolution Cups ACI with Membrane
2 Following collection, the insert is carefully removed from Cat. No. Description Cat. No. Description
the cup. 6001 NGI Dissolution Cup and Membrane Holder (each) 6003 Watchglass/PTFE Assembly for use with ACI (each)
3 The insert is covered with a pre-punched 55 mm 6002 55 mm Punch 6004 Pack of 100 Polycarbonate Filters
diameter polycarbonate membrane and secured in 6004 Pack of 100 Polycarbonate Filters (0.1 micron x 76 mm diameter)
position in a Membrane Holder, using a ring, to form a (0.1 micron x 76 mm diameter)
sealed “disc” or “sandwich”. NGI Dissolution Cup and Membrane Holder 6005 Spare Set of O-Rings
3. Dissolution Testing
We offer USP Method 2 dissolution testers for use with
the NGI and ACI Membrane Holders.
Further details about our range of dissolution testers
can be found in our sister brochure
“Driving Results in Pharmaceutical Testing”.
232 233
Inhaler Testing Improving
Ancillaries
IVIVCs
Mouthpiece Adapters
Cascade Impactor
Moulded from high quality silicone rubber, our Mouthpiece Adapters
Use of a cascade impactor allows size fractionated particles guarantee an airtight seal between the inhaler under test and the
from an aerosol cloud to be collected for testing. test apparatus.
For further information about our range of Cascade
Required for:
Impactors, please see page 82.
Nosepiece Adapters
Our Nosepiece Adapters interface the nasal device with the test system.
Required for:
Vacuum Pump
See page 203 for further information
Our Vacuum pump range represents the latest in high
performance, low maintenance technology and is,
specifically designed for use in the testing of OINDPs.
See page 188 for further information about our Qualification
Vacuum Pump range.
GMP regulations require that
• The test methods used to monitor pharmaceuticals must meet proper standards of
accuracy and reliability
• Companies should establish procedures to ensure the fitness for use of instruments
that generate data supporting product testing
Flow Controller
Copley provides a range of qualification documentation, services and tools to meet
Suitable for controlling air flow rate across the range required for
these requirements.
OINDP testing reproducibility and the ease of method transfer,
reducing potential sources of data variability. See page 302 for further information.
See page 172 for further information about our Flow Controller range.
Flow Meter
Used for establishing accurate and consistent inlet air flow
rate during testing, our range of Flow Meters measures and
controls flow within method specification.
See page 184 for further information about our range of
Flow Meters.
234 235
Inhaler Testing Improving
Ancillaries
IVIVCs
Face Models
A critical component of the test apparatus
used for facemask testing is the face model.
This should be appropriate to the age group
for which the product is intended, e.g. infant,
child or adult. Face models should:
Achieve realistic dead space Have physiologically accurate Provide a means of mounting
within the mask and at the soft facial tissue to simulate in the spacer/VHC or nebuliser
same time ensure the absence vivo conditions. such that the facemask is in
Improving IVIVCs of leaks between the mask correct alignment with the face
and model model as in “real-life” conditions.
Facemask Testing We offer a range of facemask testing systems for to allow users to utilise their own validated models, if
different devices, which seek to address the above desired. All models are fitted with replaceable face skins.
In many cases, inhaled drug products may be administered using a facemask instead of
requirements, whilst also providing sufficient flexibility
a mouthpiece. This is often the case for infants and small children and in other situations
where the user lacks the capability to use a mouthpiece.
A key factor in determining the amount of inhaled drug Due to the important role that a facemask has in
available to the patient is the interface between the transporting the drug aerosol from the device Face Model Products
facemask and the patient. A properly sized mask, firmly to the patient, further assessment is required in
Cat. No. Description
placed against the face, for example, will provide the addition to the standard DDU testing and APSD
9142 FMA/FMS Filter Holder and Adapter for BRS 100i
user with far more drug than a poorly fitting equivalent measurement methods routinely applied.
9143 FMA/FMS Filter Holder and Adapter for BRS 200i/300i
where much of the drug is lost to the environment 9103 Pack of 100 Filters for Filter Holder
through leakage. 9144 Adult Head and Adapter for FMA/FMS
9145 Child Head and Adapter for FMA/FMS
9146 Infant Head and Adapter for FMA/FMS
Relevant for two types of devices: 9149 Replacement Face Skins for Adult Head (Pack of 6)
9150 Replacement Face Skins for Child Head (Pack of 6)
9151 Replacement Face Skins for Infant Head (Pack of 6)
236 237
Inhaler Testing Improving
Ancillaries
IVIVCs
A Breathing Simulator
C Face Model
Facemask Performance
Products Featured in this System
Two types of apparatus are available, each providing standardised test methods to
quantify the effect of using a facemask on drug delivery from the device under test.
Facemask Testing Apparatus
1. Facemask Testing Apparatus (FMA) The FMA is designed to meet all the critical requirements for assessing
the impact of facemasks on performance of MDIs with a spacer/VHC.
Face Model
Models are available for all age groups - adult, child and infant. All
models are fitted with replaceable face skins which provide flexibility
and elasticity similar to real life tissue.
Position adjustable in
both axes
Filter Holder & Adapter
FMA with example valved holding Positioned in the cavity behind the lips of the face model, the holder
chamber (VHC), Face Model and
contains a filter to capture the active drug from the device under test.
MDI (face model not included
with FMA) See page 25 for further information.
238 239
Inhaler Testing Improving
Ancillaries
IVIVCs
Flow Controller
Suitable for setting flow rate and sampling time delays, as well as controlling
inhaled volume, our range of Flow Controllers improve testing reproducibility
Products Featured in this System
and the ease of method transfer, reducing potential sources of data variability.
See page 172 for further information about our Flow Controller Range.
Vacuum Pump
Face Model Our Vacuum Pump range represents the latest in high performance,
Models are available for all age groups - adult, child and infant. All low maintenance, technology, and is specifically designed for use in
models are fitted with replaceable face skins which provide flexibility the testing of OINDPs.
and elasticity similar to real life tissue.
See page 188 for further information about our Vacuum Pump range.
240 241
Inhaler Testing Improving
Ancillaries
IVIVCs
• The test methods used to monitor pharmaceuticals must meet proper standards of
accuracy and reliability
A Breathing Simulator
• Companies should establish procedures to ensure the fitness for use of instruments
that generate data supporting product testing Face Model
B
In addition to the above, the following is needed to complete a fully-operational DDU test system for assessing
the impact of facemasks on nebuliser performance:
Face Model
Models are available for all age groups - adult, child and infant. All models
Position adjustable
in both axes are fitted with replaceable face skins which provide flexibility and elasticity
Device Securing Fixture:
Secures the nebuliser and similar to real life tissue.
its associated facemask in
position prior to testing
Face Model Support accepts
three different models: infant, Filter Holder & Adapter
child and adult
Positioned in the cavity behind the lips of the face model, the holder
contains a filter to capture the active drug from the device under test.
FMS with example nebuliser See page 25 for further information.
(face model not included)
Breathing Simulator
Providing breathing profiles that are more clinically representative than a
Facemask Testing Stand (FMS) constant flow rate, the Breathing Simulator BRS 100i is ideal for assessing the
impact of a facemask on the DDU of nebulisers.
Cat. No. Description
BRS
9156 Facemask Stand for Nebulisers Model FMS Alternatively, the higher capacity Breathing Simulator Model BRS 200i can 100i
9142 FMA/FMS Filter Holder and Adapter for BRS 100i be used to access expanded functionality including the capability to apply
9143 FMA/FMS Filter Holder and Adapter for BRS 200i/300i user-defined profiles. BRS
200i
Find out more about our range of Breathing Simulators on page 156.
242 243
Inhaler Testing Improving
Ancillaries
IVIVCs
A B C D E F
The APSD characterisation of a nebuliser should be conducted using an NGI,
because it has calibrated performance at the 15 L/min test rate specified
for nebulisers.
Flow Meter
Used for establishing accurate and consistent inlet flow rate during
FMA to NGI Interface Facemask Stand Face Model Inducton Port
Accessory
A B C testing, our range of Flow Meters measure and control flow within
(FMS)
Please note – method specification.
the FMA to NGI Interface
D Cascade Impactor E Vacuum Pump E Flow Meter
Accessory is a combination See page 184 for further information.
of the base attachment (red
line) and the white interface
attachment shown in the
pop-out bubble
Vacuum Pump
Our Vacuum Pump range represents the latest in high performance,
Products Featured in this System low maintenance, technology, and is specifically designed for use in
the testing of OINDPs.
See page 188 for further information about our Vacuum Pump range.
Facemask Stand (FMS)
The FMS is designed to meet all the critical requirements for assessing
the effect of facemasks on the use of nebulisers. TOP
TIP The NGI Cooler can only be used for nebulisers with mouthpieces. For nebulisers with facemasks
the NGI will need to be removed from the NGI Cooler for testing, once the required temperature has
been reached.
In addition to the above, the following is needed to complete a fully-operational APSD measurement system for
assessing the impact of facemasks on nebuliser performance:
Qualification
Face Model
Models are available for all age groups - adult, child and infant. All models GMP regulations require that
are fitted with replaceable face skins which provide flexibility and elasticity • The test methods used to monitor pharmaceuticals must meet proper standards of
similar to real life tissue. accuracy and reliability
• Companies should establish procedures to ensure the fitness for use of instruments
that generate data supporting product testing
Filter Holder & Adapter
Positioned in the cavity behind the lips of the face model, the holder Copley provides a range of qualification documentation, services and tools to meet
contains a filter to capture the active drug from the device under test. these requirements.
See page 25 for further information. See page 302 for further information.
244 245
Inhaler Testing Improving
Ancillaries
IVIVCs
Morphology
Cascade impactors separate the delivered dose from an inhaled product on the basis
of particle inertia, producing sized fractions which are then subject to chemical assay
Cold Freon® Effect
to produce an APSD for the active drug. The cold Freon®effect is the inadvertent reaction to the chilling sensation at the
back of the throat or nasal passages following the actuation of MDIs or nasal sprays
Whilst this process provides a useful indication of where even when APSDs are equivalent. This can be
respectively, and it can significantly influence the efficiency of drug delivery.
inhaled drug particles are likely to deposit within the particularly useful in generic development when trying
respiratory tract, it does not profile the morphological to replicate the performance of a reference product. The For example, the effect may cause the patient to cough, or abort the inhalation
properties of these particles. Generating component Malvern Glass Disc Cup, allows for collection of particles manoeuvre, resulting in inconsistent dose delivery.
specific particle geometric size and shape data may on a quartz glass disk, which can then be transferred
Spray pattern and plume geometry are common measurement techniques employed by the pharmaceutical
be helpful in understanding differences between to a Malvern Panalytical Morphologi 4-ID or equivalent
industry to characterise the emitted spray from MDIs and nasal sprays. However, the reaction of the user to the
formulations and hence their potential bioavailability, system for morphological analysis.
impaction force of the spray on the throat or nasal passageways is also of much concern.
TOP TOP
TIP The ‘cold Freon®’ effect is a function TIP Cold Freon® effect assessment is important in
of aerosol spray force and plume switching propellants for MDIs. For example,
Morphology Sampling Apparatus temperature reformulation of CFC to HFA 134a and HFA 152a
246 247
Inhaler Testing Improving
Ancillaries
IVIVCs
Key Features:
Circular impaction plate – Quick-release device
Clear load cell display clamp ensures rigid
easily removed for cleaning
inhaler support
Compact footprint
Spray Force Tester SFT 1000 A sample of the inhaler to be tested is required at the time of placing an order so that a customised
clamp can be made.
The distance of the device relative to the impaction plate can be adjusted between 0 and
Adjustable Distance
200 mm +/- 0.03 mm using the precision digital gauge.
Supplied complete with calibration certificates for load cell and gauge
Memory capability for Load cell calibration
up to 100 spray force verification easily
measurements performed by user SFT 1000
248 249
Inhaler Testing Improving
Ancillaries
IVIVCs
The outlet of the PTT 1000 is normally connected to however, easily be connected directly to a DUSA See page 184 for further information about our range of Flow Meters.
a waste shot collector and vacuum pump to capture collection tube or Induction Port if preferred, since the
the measured doses at the relevant flow rate. It can, outside diameter of all three accessories are identical.
Waste Shot Collector WSC2
A compact vacuum filtration system, the Waste Shot Collector WSC2 safely
A B C D E F G captures aerosols emitted from repeated actuations of the inhaler.
See page 24 for further information.
Mouthpiece Adapters
Moulded from high quality silicone rubber, our Mouthpiece Adapters
guarantee an airtight seal between the inhaler under test and the
test apparatus.
Vacuum PTT 1000 Data Waste Shot Sampling Mouthpiece PTT 1000
A B C D E F G Flow Meter
Pump Acquisition Model Collector Manifold Adapter Software
Qualification
GMP regulations require that
• The test methods used to monitor pharmaceuticals must meet proper standards of
Products Featured in this System
accuracy and reliability
• Companies should establish procedures to ensure the fitness for use of instruments
that generate data supporting product testing
Plume Temperature Tester PTT 1000
The PTT 1000 is supplied together with the data acquisition assembly, Copley provides a range of qualification documentation, services and tools to meet
sampling manifold assembly, flow meter adapter and software. these requirements.
See page 302 for further information.
In addition to the above, the following is needed to complete a fully-operational plume temperature test system
for MDIs: Plume Temperature Tester: PTT 1000
See page 188 for further information about our Vacuum Pump range.
250 251
Inhaler Testing Aerodynamic
Special Applications
Particle
Size Distribution
AIM in QC
For OIP product batch release testing purpose once a full APSD profile has been
and QC applications, it is possible to established using a full-resolution cascade
use simpler but highly sensitive metrics impactor. This is known as Efficient Data
to determine if the product is fit for Analysis (EDA).
Typically, the APSDs of inhaled products exhibit a Normal (or Gaussian) Distribution centred around the
Mass Median Aerodynamic Diameter (MMAD). It is therefore possible to determine even subtle changes
in the APSD by measuring the following:
Abbreviated Impactor Measurement (AIM) Generic Drug Development 1. Impactor Sized Mass (ISM): the sum
of the drug mass deposited on the filter LPM/SPM sensitive to shift in APSD
The drive for greater efficiency is stimulating There is growing interest in the development and all impactor stages except the
debate as to whether full-resolution, multiple- of generic orally inhaled products (OIPs) as uppermost. This metric indicates any
stage cascade impaction can be supplemented the patents on the original products expire. shift in the amplitude of the APSD.
TOP
TIP Although EDA can be applied to full-resolution impactor testing, its true value comes from combining
it with AIM, which uses only a reduced number of impactor stages, speeding up throughput and
further reducing analytical error. Full-resolution impactor testing is then reserved for out-of-
specification (OOS) investigations.
252 253
Inhaler Testing Aerodynamic
Special Applications
Particle
Size Distribution
In this diagram, the AIM-QC model shows how abbreviating AIM - The Future
the ACI to just 2 stages and a filter, with the central stage
To meet these various demands and to provide a basis If validated and implemented, these impactors could
(Stage X) selected to have a cut-off diameter close to the
for the proof-of-concept work necessary to validate help to speed up formulation screening, prior to full
product MMAD allows the EDA metrics of ISM and LPM/SPM
to be easily determined. them, Copley has introduced a number of different resolution impactor studies being performed on the
versions of abbreviated impactor for use in both QC most promising candidates and then subsequent
The table on page 90 indicates which stage can be used for
(QC Models) and R&D (HRT Models). These are based used for product release in QC.
Stage X.
on stage versions of the popular Andersen Cascade
Adapted from: Mitchell, J.P. et al. Relative Precision of Inhaler Aerodynamic Impactor (ACI) and Next Generation Impactor (NGI).
Particle Size Distributon (APSD) Metrics by Full Resolution and Abbreviated
Andersen Cascade Impactors (ACIs): Part 1., AAPS PharmSciTechnol., 2010,
11(2): 843-851
254 255
Inhaler Testing Aerodynamic
Special Applications
Particle
Size Distribution
In addition to the FSA, the following ancillaries are required to complete a fully operational test set-up for
determining the CPM, FPM, EPM, or LPM/SPM ratio Reduced NGI (rNGI)
The individual stages of the NGI are fixed within the seal body, such that they cannot be
removed. However, the NGI can be used in an abbreviated form, the rNGI, for both AIM-QC and
AIM-HRT applications.
*Please specify Aluminium (A), 316 Stainless Steel (S) or Titanium (T) when placing your order.
256 257
Inhaler Testing Aerodynamic
Special Applications
Particle
Size Distribution
Fast Screening Impactor (FSI) In addition to the FSI, the following ancillaries are required to complete a fully operational test set-up for
determining the CPM, FPM, or LPM/SPM ratio:
Based on proven NGI Preseparator technology, the FSI represents a purpose-made approach
to AIM that separates the dose into CPM and FPM making it suitable for AIM-HRT applications
(i.e. FSI-HRT) for MDIs, DPIs and nasal sprays.
A range of inserts are available, to generate a 5 micron An additional insert is available for generating a 10
cut-off diameter within the flow rate range of 30-100 micron cut-off diameter at 30 L/min. When used
L/min at 5 L/min intervals. This makes the FSI ideal with a Glass Expansion Chamber (see page 200) this
for DPIs tested at a flow rate that equates to a 4 kPa makes the FSI ideal for the fast screening of nasal Vacuum Pump Critical Flow Controller Flow Meter
pressure drop over the inhaler. aerosols and sprays. Bespoke inserts are also available See page 188 For DPI testing only See page 184
on request with a range of cut-off diameter/flow rate See page 172
The FSI uses the same induction port as the NGI. It combinations, allowing for an FSI-QC version, with a
employs a two-stage separation process in which first cut-off diameter close to the product MMAD.
large non-inhalable boluses are captured in a liquid trap
followed by a fine-cut impaction stage at 5 microns.
This gives unparalleled accuracy, high capacity, low
internal losses and low carryover. The fine particle dose
is collected on a glass fibre filter located in an external
filter holder with quick-release catches for easy access.
Fine Fraction Collector for users that already have NGI Preseparator
5262 Fine Fraction Collector only
Note: For a complete system, users must also purchase an insert (see 5261) to replace the existing insert in their preseparator
Interchangeable Inserts
Accessories for MDIs and DPIs
5203 NGI Induction Port
8060 Flow Meter to Induction Port/WSC2 Adapter
5238 Universal Flow Meter Adapter
5204 NGI Preseparator
258 259
Inhaler Testing Aerodynamic
Special Applications
Particle
Size Distribution
Fluticasone Propionate/Salmeterol
Aerosols & Powders
The inhalation powder monographs require that DDU According to the monographs, the 28.3 L/min version
measurements be conducted for a duration consistent of the ACI (Stages 0 to 7 plus filter stage) should be
with the withdrawal of 2 litres of air. This volume is used to measure APSD for both aerosols and powders
generally considered to be representative of a typical despite the fact that the powder method specifies
patient with asthma or COPD. testing at 60 L/min.
The duration of testing for APSD measurements is
APSD measurement is conducted using a standard adjusted to give the volumetric equivalent of 3 litres
ACI equipped with a specially modified induction port of air. This is likely due to the need to achieve adequate
common to both aerosols and powders and a specially volume changes in the ACI.
modified inlet cone and preseparator for aerosols and
powders respectively.
Special Applications
The FDA has recently issued product-specific guidance A further monograph for Albuterol Inhalation Aerosol
for several active pharmaceutical ingredients (APIs) products has been approved.
that are used globally for the treatment of asthma and
In August 2020, the USP made a general announcement
COPD and are consequently routine targets for generic
for a draft guidance New Inhalation Product
development. The USP has also introduced product-
Monographs: Proposed Approach for Performance Tests
specific monographs for Fluticasone Propionate (FP)
Employing Non-standard Apparatus. This covers the use
and Salmeterol.
of current drug-specific monographs and outlines an
These product-specific monographs call for the use of approach for future monographs.
test equipment based on methods used in the original
The product-specific monographs concerned cover
development of these products.
both DDU testing and APSD measurements. DDU and
The USP list four such monographs for FP and FP/ APSD are required performance metrics for all OIPs
Salmeterol combination products: because of their defining influence on the success and Sample Collection Apparatus for Andersen Cascade Impactor (ACI)
consistency of drug delivery. FP/Salmeterol Aerosols
• Two relate to the use of the APIs as aerosols delivered
by an MDI
_ FP/Salmeterol Induction Port
• Two are for APIs prepared as inhalation powders for
delivery by a DPI
_ ACI Inlet Cone for FP/Salmeterol Aerosols
260 261
Inhaler Testing Aerodynamic
Special Applications
Particle
Size Distribution
FP/Salmeterol Powders
Apparatus requirements:
Delivered Dose Uniformity Aerodynamic Particle Size Distribution Apparatus for DDU testing of FP/Salmeterol Products
_ ACI Preseparator for FP/Salmeterol Powders Apparatus for APSD testing of FP/Salmeterol Products
_ ACI Inlet Cone for FP/Salmeterol Aerosols 8372 ACI Inlet Cone for FP/Salmeterol Aerosols*
8405 ACI Preseparator for FP/Salmeterol Powders*
8406 Set of 2 O-rings for FP/Salmeterol ACI Preseparator (Spare)
8505 FP/Salmeterol Induction Port*
In addition to the above and previous page, the following are recommended to complete a fully-operational 8505SW FP/Salmeterol Induction Port (One-piece 316 Stainless Steel)
8506 Flow Meter Adapter for FP/S Induction Port
test set-up for the DDU testing and APSD measurement of FP/Salmeterol Aerosols & Powders.
5401A FP/Salmeterol ACI Carrying/Wash Rack
* Please specify Aluminium (A) or 316 Stainless Steel (S) when placing your order.
Other
8503 Set of 2 Silicone Rubber Rinsing Caps for FP Induction Port
262 263
Inhaler Testing Aerodynamic
Special Applications
Particle
Size Distribution
The apparatus uses a solid plastic firing APSD measurement is conducted using a standard ACI
adapter, instead of a mouthpiece adapter, to equipped with a specially modified induction port. A special
Apparatus for DDU testing of Albuterol Aerosol Products
accept an inhaler with a circular mouthpiece Inlet Sleeve is available that slips over the induction port
of corresponding dimensions. Alternatively, a inlet, to enable the induction port to be used with regular Cat. No. Description
silicone Mouthpiece Adapter (page 203) can mouthpiece adapters used on USP/NGI induction ports. 8520 Sample Collection Apparatus for Albuterol Aerosol
also be used. 8524 Glass Wool (1m length)
8521 Firing Adapter
8522 Flow Meter Adapter
Delivered Dose Uniformity Aerodynamic Particle Size Distribution
* Please specify Aluminium (A) or 316 Stainless Steel (S) when placing your order.
264 265
Inhaler Testing Aerodynamic
Semi-Automation
Particle
Size Distribution
Semi-Automation
including the NGI, ACI, GTI, DUSA and waste shot
collector, the Vertus II and Vertus Plus are fully
automated benchtop shake and fire systems for
precise, controlled and reproducible MDI, nasal
spray and nasal aerosol testing.
Delivering up to a four-fold increase in throughput, semi-automation
reduces manual handling and operator input, delivering enhanced Suitable for:
reproducibility, lowering the risk of repetitive strain injury (RSI) and reducing
See page 270
overall testing costs.
We supply a broad range of semi-automation solutions supporting both
sampling and recovery for delivered dose uniformity (DDU) testing and Automated 10-Way Shake
aerodynamic particle size distribution (APSD) measurement. Our off-the- and Fire to Waste for MDIs
shelf solutions streamline validation and product testing methods and
DecaVertus II
boost test accuracy and productivity in both R&D and QC.
A high-throughput 10-way shake and fire to
waste system for highly reproducible, controlled
MDI testing.
Suitable for:
Automated Drug
Recovery for DDU Testing
DUSA Shaker
Automates the internal rinsing of both MDI
and DPI DUSA collection tubes for complete,
reproducible drug recovery.
Suitable for:
266 267
Inhaler Testing Aerodynamic
Semi-Automation
Particle
Size Distribution
Automated Cascade
Impactor Preparation
NGI Cup Coater NGI Assistant
Standardises the NGI Collection Cup coating process A complete system for drug recovery from the
guaranteeing uniform distribution of the surface NGI Collection Cup Tray, Induction Ports and
coating substance across the cups. Preseparators, boosting analytical throughput.
Recommended for:
268 269
Inhaler Testing Aerodynamic
Semi-Automation
Particle
Size Distribution
Identifying issues within the test method and limiting enable precise, controlled, reproducible testing while at
variability between analysts can be challenging, but the same time boosting productivity. Our Vertus and
inadequate control may lead to erroneous data and DecaVertus range offers extensive parameter control
consequently substantial costs to the company. and monitoring, allowing:
- Precise and easy method validation
Automated shake and fire systems enhance the
- Streamlined routine testing
sensitivity of OINDP testing and, more broadly, boost
- Cause of variation identification
data integrity by eliminating firing errors, controlling air
- Enhanced data integrity and accuracy
flow speed and automating leak testing. Such systems
Fire to Sample ✓ ✓ ✗
Shaking Leaks
Fire to Waste ✓ ✓ ✓
270 271
Inhaler Testing Semi-Automation
Key Features:
Remote support
module available
Modern intuitive
touchscreen interface
used to control all method
parameters and reporting
The Vertus II and Vertus Plus series provides analysts with absolute control
Suitable for both Improves reproducibility over a wide range of specific parameters including:
DDU and APSD and frees up analyst time
• Shaking profile (including • Time between • Firing profile (including force, pause, • Air flow through
testing
speed, angle and duration shake and fire fire down, rise and release time) the system
272 273
Inhaler Testing Aerodynamic
Semi-Automation
Particle
Size Distribution
Additional test interfaces are available, please contact us for more details.
274 275
Inhaler Testing Aerodynamic
Semi-Automation
Particle
Size Distribution
Vertus II & Vertus Plus: Technical Specifications Vertus II & Vertus Plus
Pharmacopoeial Compliance Ph. Eur., USP, Ch. P. and JP Cat. No. Description Cat. No. Description
9701 Vertus II Shake and Fire System 9720 Vertus Plus Shake and Fire System
21 CFR Part 11 Compliant ✓ 1040 Vertus II Extended Warranty - 1 year 1042 Vertus Plus Extended Warranty - 1 year
1041 Vertus II Extended Warranty - 2 years 1043 Vertus Plus Extended Warranty - 2 years
Fire Down Time ✓ Pause after fire ✓ 9705 9705 MDI Holder (per inhaler design)
9706 ACI Interface Plate with Induction Port Support Spares
Force Release Time ✓ Maximum force ✓ 9707 NGI Interface Plate
9708 NGI Interface Plate with Waste Shot Collector 9719 Thermal Transfer Printer Labels (12 Rolls of 475 each)
9715 GTI Interface Plate 9716 Direct Thermal Printer Labels (12 Rolls of 475 each)
User Interface Colour touchscreen 9710 DUSA (x4) Interface Plate with Waste Shot Collector 9712 Spare Filter Cartridge for Waste Shot Collector
9711 Waste Shot Collector with Interface Plate
Dimensions (w x d x h) 1011 x 593 x 369 mm 9718 Thermal Transfer Printer for Vertus/DecaVertus
9725 Thermal Transfer Printer Ribbon (6 Cartridges)
USB A x 2
9705L Evohaler MDI Holder
Ethernet LAN
Connectivity 9705Q Symbicort MDI Holder
Thermal transfer printer
9705T Flutiform MDI Holder
Temperature and Relative Humidity Probe
9705U Airomir MDI Holder
9901 Mouthpiece Adapter Mould (per inhaler/inlet design)
9902 Mouthpiece Adapter for ACI/NGI Induction Port and DUSA
Reported Parameters:
• User information and method ID used
• Time to fire
276 277
Inhaler Testing Semi-Automation
Key Features:
DecaVertus II
DDU testing for MDIs requires sampling throughout the TOP
TIP
life of the product and the associated firing-to-waste of
intermediate shots. The regulatory expectation is that firing The USP specifies the testing Independent airflow control Reporting available via Modern intuitive
of 10 inhalers for DDU (for to ensure each inhaler USB and Local Area touchscreen interface
to waste is carried out under representative conditions, a is tested in the same Network used to control all
testing over the entire unit
repetitive, labour-intensive process. life), with the collection of two
environment methods parameters
and reporting
samples, one at the beginning
The DecaVertus II is a state-of-the-art, fully automated, high throughput and one at the end of product
10-way shake and fire-to-waste system for MDI testing. Designed to life. In the case of a 100-dose
accommodate the entire inhaler, as used by a patient (in-actuator), it is inhaler this could mean firing
98 shots to waste, for each
equally suitable for traditional canister-only wasting.
of 10 inhalers, to complete
Automating the firing-to-waste is highly advantageous from the perspective the test.
of conserving analyst time, eliminating the risk of RSI, and maximising
the repeatability of test data; firing-to-waste under well-defined, closely TOP
TIP
controlled conditions eliminates a potential source of variability in testing. Each inhaler is tested within an identical environment; each has dedicated air flow control, dedicated firing mechanism and
a separate waste channel. This design significantly reduces the risk of inconsistent firing force or air flow, at the same time
minimising cleaning requirements and the likelihood of channel blockage.
• Shaking profile (including • Time between • Firing profile (including force, pause, • Air flow through
speed, angle and duration shake and fire fire down, rise and release time) the system
278 279
Inhaler Testing Aerodynamic
Semi-Automation
Particle
Size Distribution
Angle of Rotation ✓
Accessories (MDIs only) Spare Parts
Firing Parameter Control 9803 LAN Data Storage for ER/ES Compliance 9820 Pack of 10 Spare Waste Filter Cartridges
9704 Direct Thermal Printer for Vertus/DecaVertus 9821 Pack of 100 O-rings
Insert Force ✓ Fire down time ✓ 9716 Direct Thermal Printer Labels (12 Rolls of 475 each) 9719 Thermal Transfer Printer Labels (12 Rolls of 475 each)
9718 Thermal Transfer Printer for Vertus/DecaVertus 9725 Thermal Transfer Printer Ribbon (6 Cartridges)
Fire Force ✓ Force release time ✓ 9805L Evohaler Carriage
9805Q Symbicort pMDI Carriage
Force Rise Time ✓ Pause before fire ✓ 9805T Flutiform Carriage
9805U Airomir Carriage
9805 Carriage for MDI (per inhaler design)
User Interface Colour touchscreen 9808 Carriage for MDI Canister Only (any size)
9714 Compressor
Dimensions (w x d x h) 921 x 490 x 758 mm 9730 Vertus/DecaVertus Qualification Kit
9810 IQ/OQ Documentation for DecaVertus
USB A x 2
Connectivity Ethernet LAN
Thermal transfer printer
280 281
Inhaler Testing Aerodynamic
Semi-Automation
Particle
Size Distribution
Key Features:
Rinsing action achieved by a combination Add/remove collection
of lateral shaking and simultaneous rolling tubes at any time
of the sealed collection tubes
Ensuring full, fast and repeatable drug recovery from all internal surfaces of both MDI and no need for clamps or other fixtures
DPI DUSA collection tubes, the DUSA Shaker eliminates a time-consuming and highly variable
manual drug recovery processes. To allow rotation, the DUSA Shaker is only compatible available as Collection Tube without P1 Port
with DPI Collection Tubes that have the P1 port blanking (Cat. No. 8608A).
The automated rinsing action of the DUSA Shaker action ensures that all internal surfaces are wetted and
plug fitted. DPI Collection Tubes without the P1 port are
is achieved by a combination of lateral (side-to- that agitation is performed with a consistent, smooth
side) shaking and simultaneous rolling of the sealed but vigorous action.
collection tubes. The resultant multi-directional mixing DUSA Shaker: Technical Specifications Qualification & Maintenance
• Comprehensive IQ/OQ/PQ documentation
Shake Speed: 0 and 200 shakes per minute
packages and toolkits available
Flexible - suitable for Improves Compact benchtop Roller Rotational Speed: Fixed at 30 rpm • Qualification Kit available
both MDI and DPI reproducibility system Timer Control: Between 0 and 55 minutes • Extended Warranty available
Collection tubes and frees up
analyst time Dimensions (w x d) 570 mm x 610 mm
282 283
Inhaler Testing Aerodynamic
Semi-Automation
Particle
Size Distribution
Key Features:
Frame specifically
designed to
accept the NGI
Cup Collection Tray
Adjustable
drying time
284 285
Inhaler Testing Aerodynamic
Semi-Automation
Particle
Size Distribution
Setting a parameter Set v Actual test parameters Set v Actual test parameters
(before test run) (during test run)
USB A
Connectivity:
USB B
Dimensions (w x d x h):
Cup Coater: 590 x 280 x 185 mm Gentle Rocker
Dispenser: 150 mm x 220 mm x 130 mm
Promoting easy and fully repeatable dissolution of the active drug present in the
NGI Collection Cups following testing, the Gentle Rocker gently agitates solvent
back and forth within the cups aiding assay sample preparation.
Compliance and Maintenance NGI Cup Coater NCC 100i
• Comprehensive IQ/OQ documentation
Cat. No. Description
packages available
5920 NGI Cup Coater Model NCC 100i (excl. NGI Cup Quick and easy NGI Adjustable run time for
• Extended Warranty available Tray & Cups) sample preparation flexible testing
1034 NGI Cup Coater Extended Warranty - 1 Year
1035 NGI Cup Coater Extended Warranty - 2 Years
Accessories
20 and 40 rpm
5901 500 mL Solvent Reservoir complete with 9-way Cap models available
5902 1000 mL Solvent Reservoir complete with 9-way Cap
5903 IQ/OQ Documentation for NGI Cup Coater
5904 NGI Cup Coater Qualification Tools
5905 Recalibration of NGI Cup Coater Qualifications Tools
286 287
Inhaler Testing Aerodynamic
Semi-Automation
Particle
Size Distribution
Key Features:
Dimensions (w x d x h): 70 x 18 x 16 cm
Gentle Rocker
A number of accessories are available for the Gentle Rocker primarily designed to safeguard the integrity of
the samples concerned and maintain the condition of the collection cups which are performance critical and Accessories
particularly prone to damage.
5223 Evaporation Cover (with seals and clips to prevent solvent loss)
5255 Dust Cover (Spare)
5224 Storage Cabinet for 6 NGI cup trays (not included)
5225 IQ/OQ Documentation for Gentle Rocker
Storage Cabinet for 6 x NGI Cup Collection Trays 5235 Verification of Gentle Rocker
Accommodates up to six NGI Cup Collection Trays and 5256 Gentle Rocker Qualification Tools
their associated cups when not in use (NGI Collection 5257 Re-calibration of Gentle Rocker Qualification Tools
Cup Trays not included).
288 289
Inhaler Testing Aerodynamic
Semi-Automation
Particle
Size Distribution
Key Features:
Designed to simultaneously
accept any two fixtures
recovery procedures, alleviating testing bottlenecks and reducing the unwanted effects of
repetitive strain injury (RSI).
Variable speed control Ideal for use with Preseparator and Induction
for different dissolution Induction Ports and/or Port with Rinsing Caps
applications Preseparators
290 291
Inhaler Testing Aerodynamic
Semi-Automation
Particle
Size Distribution
SPU 200i fitted with 2 x NGI Setting a test parameter Set v Actual test parameters Set v Actual test parameters
Preseparators (before test run) (during test run)
Rotational Direction Fixtures reverse rotation direction half way through run
RS-232
Connectivity: USB A
USB B
292 293
Inhaler Testing Aerodynamic
Semi-Automation
Particle
Size Distribution
Key Features:
NGI Assistant
Automating the complete APSD measurement drug recovery process, the NGI
Assistant makes the conversion of NGI samples to solutions for HPLC analysis
simple and completely reproducible. Providing an accurate and efficient means
of recovering samples from the NGI following testing, the NGI Assistant is Accommodates dual HPLC vial
racks for collection of both primary
designed to increase throughput and protect data integrity by reducing analyst- and back-up samples for each NGI
test undertaken
related variability introduced in drug recovery procedures.
*depending on method
294 295
Inhaler Testing Aerodynamic
Semi-Automation
Particle
Size Distribution
1 2 3 4
Dispenses solvent Samples are dissolved Aspirates samples Dispenses the samples
and/or standards via gentle rocking from the NGI cups to the vials
PC-Controlled
The NGI Assistant is controlled by a separate PC, via
easy-to-use Windows-based software that provides
four default routines including:
Manual shaking Gentle agitation (of NGI cups) Automated shaking Automated drug recovery 1. Pump conditioning
(of NGI cups) 2. System priming
3. Calibration
1 run ~ 75 minutes 1 run ~ 50 minutes
4. System validation
3 runs ~ 225 minutes 3 runs ~ 140 minutes
Customer-specific routines can be configured using
additional or modified methods.
Reduce drug recovery time by up to 40%
For Health & Safety
A safety enclosure together and an emergency stop
button and provision for extraction facilities is supplied
NGI Assistant with Safety Enclosure
The most efficient way to increase throughput is by using the NGI Assistant together with the Sample as standard.
Preparation Unit SPU 200i to achieve time-savings of up to 40%.
Data from a back-to-back study reported in ONDrugDelivery, November 2020
NGI Assistant: Technical Specifications
Dispense and Reverse Cycle Time: Method dependent (8 – 12 min per NGI cup tray is typical)
Liquid Handler: 95 x 68 x 97 cm
Dimensions (w x d x h):
Safety Cabinet: 117 x 72 x 97 cm
296 297
Inhaler Testing Aerodynamic
Semi-Automation
Particle
Size Distribution
298 299
Inhaler Testing Aerodynamic
Semi-Automation
Particle
Size Distribution
Modules Only
ACI Rack
The ACI Rack has 21 apertures corresponding to the 8 stages,
the 8 Collection Plates, the Inlet Cone, Induction Port and the
2 parts of the Preseparator of the ACI.
Each rack measures 420 mm (w) x 230 mm (d) and is designed to fit inside the basket used in the Impactor
Ultrasonic Cleaning Bath. The basket prevents the carrying rack from touching the bottom or sides of the bath.
300 301
Inhaler Testing Qualification/
Aerodynamic Particle
Servicing & Training
Size Distribution
Qualification/ The USP Chapter <1058> Analytical Instrument Qualification describes in detail
the four phase approach to qualification based on design (DQ), installation (IQ),
However, these GMP regulations do not provide definitive guidance as to how these aims
are to be achieved.
Analytical Errors (Human Errors)
The USP has sought to address this problem by the introduction of a series of chapters
as follows:
Training Use of semi-automation
(see page 266)
<1058> Analytical Instrument Qualification
It is interesting to note that the scientific community has used the terms “validation” and Ways to Reduce Errors in Orally Inhaled and Nasal Drug Product (OINDP) Testing
“qualification” on an interchangeable basis thus creating a degree of ambiguity as to their
use. For this reason, USP have suggested that:
Copley recognises the scientific and regulatory importance of these initiatives.
A. The term “qualification” be applied to instrumentation Therefore, we have designed a selection of products, services and documentation
to assist you through the OINDP testing journey:
B. The term “validation” be applied to processes and software
The term “Analytical Instrument Qualification” (AIQ) is used for ensuring that an instrument
is suitable for its intended application and the term “Analytical Method Validation (AMV)”
is used for ensuring that the analytical and software procedures employed are suitable for
their intended application.
Qualification Warranty Support Training
Services See page 311 See page 312 See page 313
See page 304
302 303
Inhaler Testing Qualification/
Aerodynamic Particle
Servicing & Training
Size Distribution
Data Interpretation
Copley adopts Effective Diameter and In-Use Margin
as recognised by the European Pharmaceutical Aerosol
Group (EPAG) as a means of determining the suitability
304 305
Inhaler Testing Qualification/
Aerodynamic Particle
Servicing & Training
Size Distribution
TOP
TIP
Pinning various stages of the ACI Pinning Kit with close-up of Pin
This is a sign that the nozzles have worn, either as a result of corrosion from the solvents
used to dissolve the active drug or erosion from the constant passage of particles through
Mensuration ‘Returns’ Boxes Leak Testing
the nozzles concerned. In this case tno restoration is feasible as it is not practical to
reapply metal to impactor nozzles. Replacement of the stage will be required. 8391 ACI Mensuration ‘Returns’ Box 5233 ACI or NGI Leak Test Certificate
5292 NGI Seal Body Mensuration ‘Returns’ Box 5234 ACI or NGI Delta-P Certificate
5251 NGI Leak Tester Re-calibration
5251A Re-calibration of LTK2 Leak Test Kit tools
ED below the lower limit
Pinning Kits and Services 5442 ACI Cut-Point Particle Calibration Certificate
The vast majority of impactors tend to drift out of specification because ED decreases below the
lower limit for the stage. This can be caused by a build-up of hardened particulates or, more likely, 5430 ACI Pinning Service (per stage)
because corrosion produces metal salts that occlude the nozzle. The formation of oxidised impurities 5431 ACI Pinning Kit
at the nozzle exit is a commonly encountered cause of occlusion, particularly for aluminium 5432 NGI Pinning Service (per stage)
impactors, which is why materials such as stainless steel and titanium are often also used. 5433 NGI Pinning Kit
In this case of ED below the lower limit, performance can sometimes be improved or restored.
Rigorous cleaning and ultrasonics (see page 298 for the Impactor Cleaning System) can be used to
remove deposits and restore performance.
Stage Pinning can also be attempted as a secondary option. Pushing stainless steel “go” pins with
a diameter between the nominal diameter and the lower tolerance limit for the stage through each
nozzle can serve to clear accumulated debris.
Stage Replacement is recommended in cases that the restoration of the impactor stage is not
achievable via stage pinning.
306 307
Inhaler Testing Qualification/
Aerodynamic Particle
Servicing & Training
Size Distribution
What is included?
308 309
Inhaler Testing Qualification/
Aerodynamic Particle
Servicing & Training
Size Distribution
Qualification Tools
Delta-P
Nozzle dimensional performance can be indirectly monitored
by measuring the pressure drop (Delta-P) across each stage of
the impactor at a particular flow rate. Theoretically, for example,
a 2% shift in ECD corresponds to an approximate 5% shift in
Delta-P. Delta-P can be measured by the addition of a pressure
port at each impactor stage. In the case of the NGI, this is
achieved by means of a specially designed lid in conjunction
with the TPK 100i/R (see page 180). It is then a simple matter to
determine the pressure drop across each stage using a sensitive
Warranty
pressure meter.
Standard 12 Months Warranty
Copley offers a 12 months supplier’s warranty as standard with our entire product range.
A B
Extended Warranty
Anti-Electrostatic Equipment
For selected items, Copley offers the option to obtain extended warranty for a further period
A - Antistatic Grounding Kit
of 12 or 24 months after the standard warranty expires. We have confidence in our excellent
B - Electrostatic Eliminator
product quality but an extended warranty provides the peace of mind that comes with an
C
C - Digital Static Meter added layer of assurance.
Products that extended warranty is available for:
Qualification Tools
Ancillaries and Semi Automation
Cat. No. Description
Equipment Qualification Kits
5440 Inhaler Testing Qualification Kit Model ITQK2
Flow Controllers Vacuum Pumps Breathing Simulators Semi-Automation Tools
Separate tools are required for the 5445 Re-calibration of ITQK2 Kit tools
see page 172 see page 188 see page 156 see page 266
qualification of various ancillaries and semi 5216 ‘Delta-P’ Apparatus for NGI
automation equipment. Please refer to the 5217 NGI Leak Tester
relevant chapters for more information
Electrostatic Effects Minimisation
9300 Antistatic Grounding Kit
9301 Electrostatic Eliminator
9302 Digital Static Meter
310 311
Inhaler Testing Qualification/
Aerodynamic Particle
Servicing & Training
Size Distribution
Design Support
Our design team has many years’ experience
working closely with the inhaler testing
community in helping to develop ideas for solving
particular problems.
Whether you have a longstanding problem, or one As a world leader in the provision of equipment for testing OINDPs, Copley offers a range of
that has been created by the introduction of a tailored training packages for both analysts and lab managers of pharmaceutical companies.
new process, an idea for a new product, or even a
Training is planned and executed according to your exact requirements and can focus on both application and
bespoke design that you need manufacturing, we
installation/qualification topic areas.
would be delighted to hear from you.
Please contact us to find out more about our range of training packages.
Contact us at: sales@[Link]
or call: +44 (0)115 961 6229
312 313
Inhaler Testing Index
Index
A B D F I N
Abbreviated Impactor Book, Reference 309 Delta-P Testing 310 Fine Particle Dose (FPD) Installation Qualification 308, 309-310 Nasal Aerosols 10, 64-68, 141-146
Measurement (AIM) 252, 253-259 Breath Actuation Design 312 76, 80, 98, 141, 147, 200, 210, 215 Internal Filter Holder, NGI 85, 87 Nasal Delivery Systems 10
ACI 77, 88-93 Controller BAC 100i 176-179 Device Resistance 42, 90, 116, 172-173 Fine Particle Fraction (FPF) 80 International Pharmaceutical Nasal, Idealised 222
ACI Carrying/Wash Rack 92, 300 Breath-Actuated MDIs 7, 20, 21, 102, 172 DFM 2000 Flow Meter 185, 187 Fine Particle Mass (FPM) 76, 254, 258 Consortium on Regulation and Nasal Powders 10, 70-74, 147-152
ACI, Cleaning 298-301 Breathing Flow Controllers: Science (IPAC-RS) 16, 17
DFM 4 Flow Meter 185, 186 Nasal Spray Modification,
ACI Cleaning System 298-301 Simulators 25, 154, 156-171 - TPK-100i 180-183 International Standards Twin Impinger 99, 100
Dissolution Cup 232, 233
Bounce, Particle 94, 102, 116, 284 Organisation (ISO) 2, 14, 16, 17
ACI Collection Plate Rack 91, 93 Dissolution Inhaled 230-235 - TPK 100i-R 180-183 Nebulisers 9, 48-52, 122-127
BP Content Uniformity Apparatus 25 Inter-Stage Losses 83, 94, 98
ACI Drying Oven 299, 301 Dissolution Testing - BAC 100i 176-179 Nebulisers, Delivered Dose 48-52
In vitro - in vivo
ACI Pinning Kit 307 – Dose Collection 231-233 - BAC 100i-R 176-179 Nebulisers, Particle Size 122-127
correlation 14, 79, 156, 157, 214-217
ACI Pinning Service 307 C Dosage Unit Sampling Apparatus Flow Meters 184-187 In-Use Margin 305 Next Generation Impactor (NGI) 82-87
ACI Rinse Bath 299, 301 (DUSA) for DPIs 22-23 Flow Rate 173, 184, 185 IPAC-RS 16, 17 NGI 82-87
Caps, Rinsing 291, 293
ACI Sample Preparation Unit 290-293 Dosage Unit Sampling Apparatus Flow Rate Stability 174 IQ/OQ Documentation 309 NGI + 83, 87
Carrying/Wash Rack ACI 92, 300 (DUSA) for MDIs 21
ACI Suction Aspirator 299, 301 Flow Resistance 22, 42, 44, 173, 216, 257 ISO 20072 16, 17 NGI Assistant 294-297
Carrying/Wash Drug Delivery Devices 6-11
ACI Ultrasonic Cleaning Bath 299, 300, 301 Fluticasone Propionate Aerosols ISO 27427:2013 17, 158, 162, 167 NGI Carrying/Wash Rack 86, 300
Rack, NGI 86, 87, 300, 301
Active Pharmaceutical Ingredient (API) 18, 78 Drug Losses, Inter-Stage 83, 94, 96 - Testing 261, 263 NGI Cooler 194-195
Cascade Impactors 78-81, 82-101 ISO 9001:2015 Quality
Active Substance Delivery Drying Oven, ACI 299, 301 Fluticasone Propionate Powders Management System 2 NGI Cup Coater 284-286
CDER 12, 16, 17
Rate (Nebulisers) 48, 49 Dry Powder Inhalers (DPIs) 8 - Testing 261, 262, 263 ITW 196-199 NGI Cup Tray Storage Cabinet 288, 289
CDRH 12
Actuation Sensor for MDIs 179 DUSA Shaker 267, 282-283 Food and Drug IVIVC 14, 79, 156, 157, 214-217 NGI Gentle Rocker 287-289
Chinese Pharmacopoeia (ChP) 16, 17
Adapters, Mouthpiece 203-205 Administration (FDA) 12, 13, 14, 16, 17 NGI Gravimetric Cup 85, 87
Cleaning Systems, ACI/NGI 298-301
Adapters, Nosepiece 203, 205 NGI Leak Tester 310
Coarse Particle Mass (CPM) 254, 256, 258 E J
Add-on Devices 7, 28, 36-40, 109-114 NGI Pinning Kit 307
Coating, Cups 102, 116, 120, 268, 284-286 G
Aerodynamic Particle Size (APSD) 13, 76-153 Effective Cut-off Diameter (ECD) 90, 310 Japanese Pharmacopoeia (JP) 16, 17 NGI Pinning Service 307
Cold Freon® Effect 247-251
AIM - HRT Model 255-258 Efficient Data Analysis (EDA) 253 Generic Drug Development 260-265 Jet Nebulisers 9 NGI Plus 83, 87
Collection Tubes for DPIs 22-23
AIM - QC Model 253-256 Electrostatic Effects 310 Glass Expansion Chambers 200-202 NGI, Reduced (rNGI) 257
Collection Tubes for MDIs 21
AINI 222 Electrostatic Eliminator 310 Glass Impinger 98-100 NGI Sample Preparation Unit 268, 290-293
Connectors, Quick-Release 199 L
Alberta Idealised Nasal Inlet (AINI) 222 Emitted Dose 18, 230 Glass Twin Impinger 98-100 Nosepiece Adapters 203, 205
Conversion Kits, 60 & 90 L/min 93
Alberta Idealised Throat (AIT) 220-221 Entire Contents (DDU) 19, 20, 29, 37, 43 Gentle Rocker 287-289 Large Particle Mass (LPM) 253, 254
Cooler, NGI 194-195
Albuterol Aerosols, Testing 26, 264-265 European Medicines Geometric Standard Deviation (GSD) 80, 82 Leak Testing 81, 176, 180, 272, 307
Critical Quality Attributes (CQAs) 15, 18, 76, 216 Agency (EMA) 12, 14, 17 O
Analytical Instrument Global Harmonisation Task Force (GHTF) 14 Leak Test Kit 307
Qualification (AIQ) 302, 303 Critical (Sonic) Flow 174, 180, 191 European Pharmaceutical Gravimetric Cup, NGI 85, 87 Losses, Inter-Stage 83, 94, 98
Cup Coater 284-286 Aerosol Group (EPAG) 16, 17, 195, 305 OINDPs 6-11
Analytical Method Validation (AMV) 302, 303 Losses, Wall 82
Cut-Off Diameter European Pharmacopoeia Operation Qualification 309
Ancillaries 154-205
84, 90, 96, 99, 208, 255, 257, 258 ([Link].) 15 I Organisations 12-17
Andersen Cascade/Impactor (ACI) 88-93, 233
Cup Tray Storage Cabinet, NGI 288, 289 External Filter Holder, NGI 85, 87, 209, 258 M
Andersen Fast Screening ICH Guidelines 14
Impactor (FSA) 255-256 Extra-fine Particle Mass (EPM) 254, 257
Idealised Nasal 222 Mass Balance 82 P
Antistatic Grounding Kit 310 D Idealised Throat 220-221 MDI Actuation Sensor 158, 179, 183
APSD 13, 76-153 F P1 Measurement Adapter 118
Impactor Choice 101 MDI Angle of Rotation 276, 280
Aqueous Droplet Inhalers 6, 10, 54-58, 128-133 Data Analysis Software (Inhalytix) 206-212 Particle Bounce 94, 102, 116, 284
Impactor Cleaning System 298-301 MDI Semi-Automation 270-281
Assistant, NGI 269, 294-297 DecaVertus II 278-281 Facemask-based products 217, 236-245 Particle Size 76-81
Impactor Performance Testing 304-307 MDI Shake and Fire 267, 270-281
Automated Fire 267, 270-277 Delivered Dose Sampling Apparatus for: Facemask Stand for Nebulisers Pharmacopeial Forum 15
(FMS) 242-245 Impactor Qualification 304-307 Mensuration (impactor) 81, 304-307
Automated Flow Control 172-183 - Nebulisers with a Mouthpiece 48-51 Pharmeuropa 15
Facemask Test Apparatus for Impactor Sized Mass (ISM) 218, 220, 253 Mesh Nebulisers 9
Automated Nasal - Nebulisers with a Facemask 242-243 [Link]. 15
Spacers and VHCs (FMA) 238-241 Impinger, Glass, Twin 98-100 Meter, Flow 184-187
Testing System 26, 61, 138, 275 - Spacers & VHCs 36-39 Pinning Kits 307
Fast Screening Andersen (FSA) 255-256 Inhaled Dissolution 230-235 Meter, Static 310
Automated Shake 267, 270-277 Delivered Dose Uniformity (DDU) 18-74 Pinning Service 307
Fast Screening Impactor (FSI) 258-259 Inhaled Drug Products 6-11 Metered-Dose Inhalers (MDIs) 7, 28-40, 102-114
Automated Shake and Fire 267, 270-281 Plume Temperature Testing 250-251
Fast Screening Impactors 255-259 Inhaler Testing Software (Inhalytix) 206-213 Metered Nasal Spray Pump 10
Automation 266-301 Powder-Based
Fast Screening NGI (rNGI) 257 Inhaler Testing Workstation (ITW) 196-199 MHLW (Japan) 12, 14
Nasal Devices 10, 70-74, 147-152
Inhalytix Software 206-213 Mitutoyo QV404 Vision
Inspection System 305 Pressure Drop
Inlet, Mixing 219, 226 22, 42, 44, 70, 90, 116, 118, 173, 310
Inspiration Volumes 173, 174 Mixing Inlet 219, 226
Process Analytical
Mouthpiece Adapters 203-205
Technologies (PAT) 14
Multi-Stage Liquid
Product Quality Research
Impinger (MSLI) 94-96
Institute (PQRI) 16
314 315
Inhaler Testing Index
Aerodynamic Particle
Size Distribution
P S U Notes
Propellant-Based Nasal Aerosols 6, 10 Salmeterol Aerosols, Testing 260, 261-263 Ultrasonic Cleaning Bath, ACI 299, 301
PTT 1000 Plume Temperature Tester 250-251 Salmeterol Powders, Testing 260, 261-263 Ultrasonic Nebulisers 6, 9
Pumps, Vacuum 155, 188-192 Sample Preparation Unit 268, 290-293 United States Pharmacopeia (USP) 15, 17
PVC Tubing 199 Semi-Automation 266-301
Semi-Automation (NGI) 284-301
V
Semi-Automation (MDI) 270-281
Q
Servicing (Qualification) 302-308 Vacuum Pumps 155, 188-192
Qualification 302 Shake and Fire 267, 270-281 Validation 302
Qualification, Servicing & Training 302-313 Shaker, DUSA 267, 282-283 Valved Holding
Qualification Documentation IQ/OQ 309 Simulators, Breathing 25, 154, 156-171 Chambers (VHCs) 7, 36-40, 109-114
Qualification Tool Kit 310 Small Particle Mass (SPM) 253, 254 Verification 302
316 317
Inhaler Testing Notes
Aerodynamic Particle
Size Distribution
318 319
Inhaler Testing Notes
Aerodynamic Particle
Size Distribution
320 321
Inhaler Testing Notes
Aerodynamic Particle
Size Distribution
322 323
Austria, France, Germany and Switzerland
Copley Scientific AG
Erlenstrasse 27
Postfach 152
CH-4106 Therwil
Switzerland